

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2023 OF THE CONDITION AND AFFAIRS OF THE

Wellmark, Inc.

NAIC Group C		C Company Code <u>88848</u> Employe	er's ID Number <u>42-0318333</u>
Organized under the Laws of	(Current) (Prior) lowa	, State of Domicile or Port	of EntryIA
Country of Domicile		United States of America	
Licensed as business type:		Life, Accident & Health	
Is HMO Federally Qualified? Yes [] No []		
Incorporated/Organized	09/19/1939	Commenced Busines	s 10/01/1939
Statutory Home Office	1331 Grand Avenue		Des Moines, IA, US 50309-2901
otatatory Figure Office	(Street and Number)	, (C	ity or Town, State, Country and Zip Code)
Main Administrative Office		1331 Grand Avenue	
Des Moine	es, IA, US 50309-2901	(Street and Number)	515-376-4500
	tate, Country and Zip Code)		(Area Code) (Telephone Number)
	1331 Grand Avenue		Des Moines, IA, US 50309-2901
(S	treet and Number or P.O. Box)	(C	ity or Town, State, Country and Zip Code)
Primary Location of Books and Record	s	1331 Grand Avenue (Street and Number)	
	es, IA, US 50309-2901	(Street and Number)	515-376-4500
(City or Town, S	tate, Country and Zip Code)		(Area Code) (Telephone Number)
Internet Website Address		www.wellmark.com	
Statutory Statement Contact	Ashley Ariel Arelland	,	515-376-6307
arelland	(Name) paa@wellmark.com	,	(Area Code) (Telephone Number) 515-376-9054
(E	-mail Address)		(FAX Number)
		OFFICERS	
President & CEO		EVP, CFO & Treasure	er David Seth Brown
Secretary	Scott Andrew Sundstrom		
Marcelle Jo Chicker	ring	OTHER John Thomas Clendenin	G. Paul Eddy
Laura Jean Jackso Sean Joseph McTag	on	Christa Daneen Kuennen Naim Anwar Munir MD	Jared Blayne Landin Keith Yatish Shah
осан зозерн метад			Kelti Tatish Shah
Cory Randall Harr	= ::	RECTORS OR TRUSTEES Daryl Keith Henze - Chairman	William Curt Hunter
Douglas Dwight La Angeline Marie Lav		Harlan John Langstraat # Timothy John Theriault	Paul Edward Larson David Arthur Vaudt
Therese Michele Vau		Timothy conit Thenaut	Bavid / William Vaddi
	owa Polk		
·			
all of the herein described assets wer statement, together with related exhibit condition and affairs of the said reporti in accordance with the NAIC Annual S rules or regulations require difference respectively. Furthermore, the scope	e the absolute property of the said is, schedules and explanations there no entity as of the reporting period statement Instructions and Accounting in reporting not related to account this attestation by the described of	reporting entity, free and clear from any in contained, annexed or referred to, is a ated above, and of its income and deducing Practices and Procedures manual excunting practices and procedures, acconfficers also includes the related corresponding to the containing practices.	d reporting entity, and that on the reporting period stated above, liens or claims thereon, except as herein stated, and that this full and true statement of all the assets and liabilities and of the tions therefrom for the period ended, and have been completed ept to the extent that: (1) state law may differ; or, (2) that state rding to the best of their information, knowledge and belief, anding electronic filing with the NAIC, when required, that is an may be requested by various regulators in lieu of or in addition
Cory Randall Harris President & CEO		Scott Andrew Sundstrom Secretary	David Seth Brown EVP, CFO & Treasurer
Subscribed and sworn to before me thi	s	b. If no,	I filing? Yes [X] No [] endment number

3. Number of pages attached.....

ASSETS

	7.0	OLIO	Current Year		Prior Year
		1	2	3	4
		•	_	Net Admitted Assets	Net Admitted
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets
1.	Bonds (Schedule D)	1,046,468,772	0	1,046,468,772	855,820,270
2.	Stocks (Schedule D):				
	2.1 Preferred stocks	2,273,928	552,485	1,721,443	2,395,118
	2.2 Common stocks		56,690,394	1,413,067,061	1,335,457,848
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens	0	0	0	0
	3.2 Other than first liens	0	0	0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)	126 424 760	27 424 760	99 000 000	99 000 000
	4.2 Properties held for the production of income (less	120,424,700	27,424,700		
		0	0	0	0
	· · · · · · · · · · · · · · · · · · ·	0	0		
	4.3 Properties held for sale (less \$0			_	_
	encumbrances)	0	0	0	0
5.	Cash (\$283,786,334 , Schedule E - Part 1), cash equivalents				
	(\$215,758,641 , Schedule E - Part 2) and short-term				
	investments (\$	508,858,472	0	508,858,472	325,027,163
6.	Contract loans, (including \$0 premium notes)	0	0	0	0
7.	Derivatives (Schedule DB)	0	0	0	0
8.	Other invested assets (Schedule BA)	321,967,228	8,883,851	313,083,377	236, 149, 205
9.	Receivables for securities	8.733.811	0	8.733.811	672.893
10.	Securities lending reinvested collateral assets (Schedule DL)				· ·
11.	Aggregate write-ins for invested assets				
12.	Subtotals, cash and invested assets (Lines 1 to 11)				
	Title plants less \$0 charged off (for Title insurers	0, 404, 404, 420			2,004,022,407
13.	only)	0	0	0	0
4.4	**				
14.	Investment income due and accrued	9,211,511	U	9,277,577	
15.	Premiums and considerations:			24 424 242	
	15.1 Uncollected premiums and agents' balances in the course of collection	91,104,216	0	91,104,216	82,4/5,/16
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$0				
	earned but unbilled premiums)	0	0	0	0
	15.3 Accrued retrospective premiums (\$3, 139,828) and				
	contracts subject to redetermination (\$21,070,000)	24,209,828	0	24,209,828	19,514,879
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers	0	0	0	0
	16.2 Funds held by or deposited with reinsured companies	0	0	0	0
	16.3 Other amounts receivable under reinsurance contracts				0
17.	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon				30,396,654
	Net deferred tax asset				53,152,000
	Guaranty funds receivable or on deposit				
19.	· · · · · · · · · · · · · · · · · · ·				
20.	Electronic data processing equipment and software		6, 163,290		1,5/1,8/9
21.	Furniture and equipment, including health care delivery assets				
	(\$0)				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$66,229,864) and other amounts receivable				
25.	Aggregate write-ins for other than invested assets	65,032,193	64,519,923	512,270	507,584
26.	Total assets excluding Separate Accounts, Segregated Accounts and				
	Protected Cell Accounts (Lines 12 to 25)		275 , 150 , 111	3,907,004,071	3,308,799,411
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0	0	0
00					
28.	Total (Lines 26 and 27)	4, 182, 154, 182	275, 150, 111	3,907,004,071	3,308,799,411
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
2501.	Prepaid Premium Tax Assets	13,891.586	13,891.586	0	0
2502.	Prepaid Pension Costs			0	0
2503.	Other Prepaid Expenses			0	0
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2596. 2599.		65,032,193		512,270	
2099.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	00,032,193	04,319,923	312,2/0	JU1, J84

LIABILITIES, CAPITAL AND SURPLUS

			Current Year		Prior Year
		1	2	3	4
		0		T. ()	T-4-1
	•	Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$0 reinsurance ceded)				
2.	Accrued medical incentive pool and bonus amounts			3,410,000	
3.	Unpaid claims adjustment expenses	4,058,760	0	4,058,760	3,535,954
4.	Aggregate health policy reserves, including the liability of				
	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	64,509,978	0	64,509,978	70,915,662
5.	Aggregate life policy reserves	0	0	0	0
6.	Property/casualty unearned premium reserves	0	0	0	0
7.	Aggregate health claim reserves	0	0	0	0
8.	Premiums received in advance				
9.	General expenses due or accrued				
10.1		,,			,,
	(including \$0 on realized capital gains (losses))	0	0	0	0
10.2	Net deferred tax liability				
11.	Ceded reinsurance premiums payable				
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated	192,297,292		192,297,292	22,295,940
14.	Borrowed money (including \$0 current) and				
	interest thereon \$0 (including				
	\$0 current)				
15.	Amounts due to parent, subsidiaries and affiliates	114,722,610	0	114,722,610	125,299,310
16.	Derivatives	0	0	0	0
17.	Payable for securities	91,510,740	0	91,510,740	50,361,001
18.	Payable for securities lending	0	0	0	0
19.	Funds held under reinsurance treaties (with \$0				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)	0	0	0	0
20.	Reinsurance in unauthorized and certified (\$0)				
20.	companies		0		0
21.	Net adjustments in assets and liabilities due to foreign exchange rates				
22.	Liability for amounts held under uninsured plans	107,204,954		107,204,954	106,769,099
23.	Aggregate write-ins for other liabilities (including \$				
	current)				
24.	Total liabilities (Lines 1 to 23)		0	1,266,469,386	1,028,017,615
25.	Aggregate write-ins for special surplus funds				
26.	Common capital stock	XXX	XXX	0	0
27.	Preferred capital stock	XXX	XXX	0	0
28.	Gross paid in and contributed surplus				
29.	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)				
32.	Less treasury stock, at cost:				2,200,701,700
32.	•				
	32.10 shares common (value included in Line 26	2004	2007		
	\$	XXX	XXX	u	0
	32.2				
	\$0)				
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)				
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	3,907,004,071	3,308,799,411
	DETAILS OF WRITE-INS				
2301.	Other Liabilities	8,896,335	0	8,896,335	11,008,983
2302.	Health Assessments	9,190,000	0	9,190,000	7,600,000
2303.	Payments in Process	134,981,025	0	134,981,025	124,765,397
2398.	Summary of remaining write-ins for Line 23 from overflow page			3,018,294	
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	156,085,654	0		145,845,536
2501.				, ,	
2502.					
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	0
3001.					
0000					
3002.				Ĩ	İ
3002.					

STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN			D: 1/
		Curren 1	t Year 2	Prior Year 3
		Uncovered	Total	Total
1.	Member Months	xxx	13,565,905	13,661,152
2.	Net premium income (including \$	XXX	2,615,179,412	2,576,337,134
3.	Change in unearned premium reserves and reserve for rate credits	XXX	6 650 684	(5 762 410)
4.	Fee-for-service (net of \$0 medical expenses)			
5.	Risk revenue			
6.	Aggregate write-ins for other health care related revenues			0
7.	Aggregate write-ins for other non-health revenues	XXX	0	0
8.	Total revenues (Lines 2 to 7)	XXX	2,621,830,096	2,570,574,724
	Hospital and Medical:			
9.	Hospital/medical benefits	0	1,446,352,894	1,448,955,869
10.	Other professional services	0	278,739,254	267,281,695
11.	Outside referrals	0	82,010,668	
12.	Emergency room and out-of-area	0	99 276 071	97 897 355
	Prescription drugs			322.622.882
13.	•			- , ,
14.	Aggregate write-ins for other hospital and medical			
15.	Incentive pool, withhold adjustments and bonus amounts			
16.	Subtotal (Lines 9 to 15)	0	2,248,771,981	2,238,058,571
	Less:			
17.	Net reinsurance recoveries	0	0	0
18.	Total hospital and medical (Lines 16 minus 17)	0	2,248,771,981	2,238,058,571
19.	Non-health claims (net)	0	0	0
20.	Claims adjustment expenses, including \$20,674,965 cost containment expenses			
	General administrative expenses			
21.	·	0	200,116,325	200,614,192
22.	Increase in reserves for life and accident and health contracts (including \$0			
	increase in reserves for life only)			
23.	Total underwriting deductions (Lines 18 through 22)	0	2,535,185,011	2,519,076,077
24.	Net underwriting gain or (loss) (Lines 8 minus 23)	XXX	86,645,085	51,498,647
25.	Net investment income earned (Exhibit of Net Investment Income, Line 17)	0		114,833,891
26.	Net realized capital gains (losses) less capital gains tax of \$			
27.	Net investment gains (losses) (Lines 25 plus 26)		198,704,598	
			100,704,000	
28.	Net gain or (loss) from agents' or premium balances charged off [(amount recovered	_	_	_
	\$0) (amount charged off \$0)]0			
29.	Aggregate write-ins for other income or expenses	0	(1,980,543)	(3,722,487)
30.	Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus	2007	000 000 140	105 770 001
	27 plus 28 plus 29)			
31.	Federal and foreign income taxes incurred	XXX	66,836,000	23,410,000
32.	Net income (loss) (Lines 30 minus 31)	XXX	216,533,140	82,368,021
	DETAILS OF WRITE-INS			
0601.		XXX		
0602.		xxx		
0603		xxx		
0698.	Summary of remaining write-ins for Line 6 from overflow page			0
0699.	Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.	Totals (Lines door till a door plus door), Line o above)			ű
0701.				
0702.				
0798.	Summary of remaining write-ins for Line 7 from overflow page			
0799.	Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.				
1402.				
1403.				
1498.	Summary of remaining write-ins for Line 14 from overflow page	0	0	0
1499.	Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0	0
2901.	Other Expense	0	(1,980,543)	(3,722,487)
2902.				
2903				
2998.	Summary of remaining write-ins for Line 29 from overflow page	0	0	0
2999.	Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	(1,980,543)	(3,722,487)
	,	<u> </u>	, ,,,-,-,0)	, - , · == , ·•· /

STATEMENT OF REVENUE AND EXPENSES (Continued)

	STATEMENT OF REVENUE AND EXPENS	1	2
		Current Year	Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	2,280,781,796	2,317,773,599
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$	95,539,888	(72,810,655
37.	Change in net unrealized foreign exchange capital gain or (loss)	8,022,074	(8,321,805
38.	Change in net deferred income tax	24,834,000	5,041,000
39.	Change in nonadmitted assets	(2,807,178)	(38,554,833
40	Change in unauthorized and certified reinsurance	0	C
41.	Change in treasury stock	0	C
42.	Change in surplus notes	0	C
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus	0	0
45.	Surplus adjustments:		
	45.1 Paid in	0	C
	45.2 Transferred to capital (Stock Dividend)	0	C
	45.3 Transferred from capital	0	C
46.	Dividends to stockholders	0	C
47.	Aggregate write-ins for gains or (losses) in surplus	17,630,965	(4,713,531
48.	Net change in capital and surplus (Lines 34 to 47)		(36,991,803
49.	Capital and surplus end of reporting period (Line 33 plus 48)	2,640,534,685	2,280,781,796
	DETAILS OF WRITE-INS		
4701.	Change in Pension and Other Postemployment Benefit Obligation	17,630,965	(4,713,531
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page		
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	17,630,965	(4,713,5

CASH FLOW

	3, (3111 2311		
		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	2,608,844,764	2,548,835,111
2.	Net investment income	109,529,600	82, 132, 797
3.	Miscellaneous income	0	0
4.	Total (Lines 1 through 3)	2,718,374,364	2,630,967,908
5.	Benefit and loss related payments	2,241,993,680	2,389,125,317
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	0	0
7.	Commissions, expenses paid and aggregate write-ins for deductions		302,683,086
8.	Dividends paid to policyholders		0
9.	Federal and foreign income taxes paid (recovered) net of \$		12,747,486
10.	Total (Lines 5 through 9)		2,704,555,889
11.	Net cash from operations (Line 4 minus Line 10)		(73,587,981
11.	Net dash from operations (Line 4 minus Line 10)	72,002,010	(70,307,301
	Orale from Investments		
40	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:	1 150 000 070	700, 000, 400
	12.1 Bonds		
	12.2 Stocks	, , ,	-,,-
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		, ,
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		(6,447
	12.7 Miscellaneous proceeds	41,149,739	45,084,972
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	1,432,600,530	834,991,661
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds	1,360,147,016	625,555,603
	13.2 Stocks	169,926,099	212,752,549
	13.3 Mortgage loans	0	0
	13.4 Real estate	1,005,856	3,273
	13.5 Other invested assets	80,324,000	62 , 158 , 487
	13.6 Miscellaneous applications	8,270,242	279, 141
	13.7 Total investments acquired (Lines 13.1 to 13.6)	1,619,673,213	900,749,053
14.	Net increase/(decrease) in contract loans and premium notes		0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)		(65,757,392
10.	The Cash Hall Investments (Enter 12.5 Hillias Enter 16.7 Hillias Enter 17)	(107,072,000)	(00,101,002
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
10.	16.1 Surplus notes, capital notes	0	0
	•		
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds		
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders	0	0
	16.6 Other cash provided (applied)	298,271,979	238,346,586
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	298,271,979	238,346,586
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	183,831,309	99,001,213
19.	Cash, cash equivalents and short-term investments:		
	19.1 Beginning of year	325,027,163	226,025,950
	19.2 End of year (Line 18 plus Line 19.1)	508,858,472	325,027,163
		- 1	
	upplemental disclosures of cash flow information for non-cash transactions:		
	1 Noncash dividend from subsidiary	89.500.000	43.500.00

Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0001 Noncash dividend from subsidiary	89,500,000	43,500,000
		1

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

				AL I DID	OI OI		ם פות	LINES	OI DO						
		1		hensive	4	5	6	7	8	9	10	11	12	13	14
			(Hospital 8	& Medical) 3				Federal							
		Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Net premium income	2,615,179,412	93,668,300	1,351,105,528	461,646,882	1, 194,818	35,679,803	319,649,085		00	0	0	0	352,234,996	0
2.	Change in unearned premium reserves and reserve														
	for rate credit	6,650,684	68,451	(2,773,025)	18,653	0	(4, 109) 8,502,826	0	00	0	0	0	837,888	0
3.	Fee-for-service (net of \$0														
	medical expenses)	0	0	0	0	0	0	0	0	00	0	0	0	0	XXX
4.	Risk revenue	0	0	0	0	0	0	0	0	00	0	0	0	0	XXX
5.	Aggregate write-ins for other health care related revenues	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related revenues	0	XXX	XXX	xxx	xxx	XXX	xxx	xxx	xxx	xxx	xxx	xxx	XXX	0
7.	Total revenues (Lines 1 to 6)	2,621,830,096	93,736,751	1,348,332,503	461,665,535	1, 194,818	35,675,694	328, 151, 911		00	0	0	0	353,072,884	0
8.	Hospital/medical benefits	1,446,352,894	51,456,927	730,966,567	300,410,471	0	0	163,700,418	0	00	0	0	0	199,818,511	XXX
9.	Other professional services	278,739,254	8,859,912	125,858,651	51,725,016	935,807	28,768,766	28, 186, 124	0	00	0	0	0	34,404,978	XXX
10.	Outside referrals	82,010,668	2,917,695	41,447,048	17,033,784	0	0	9,282,092	0	00	0	0	0	11,330,049	XXX
11.	Emergency room and out-of-area	99,276,071	3,531,947	50, 172, 741	20,619,844	0	0	11,236,217	0	00	0	0	0	13,715,322	XXX
12.	Prescription drugs	329,894,368	12,870,363	200, 122, 932	3,255	0	0	88,478,250	0	00	0	0	0	28,419,568	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	00	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus	10 100 700													
	amounts	12,498,726	860,829	11,637,897	0		0	0	0	0	0	0	0	0	XXX
15.	Subtotal (Lines 8 to 14)	2,248,771,981	80,497,673	1, 160, 205, 836	389,792,370	935,807	28,768,766		0	0	0	0	0	287,688,428	XXX
16.	Net reinsurance recoveries	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
17.	Total medical and hospital (Lines 15 minus 16)	2,248,771,981	80,497,673	1,160,205,836	389,792,370	935,807	28,768,766		0	0	0	0	0	287,688,428	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19.	Claims adjustment expenses including	86.294.705		31,953,199	12.682.699		1,551,458	18.918.937			0	0		19.540.006	0
20.	\$	200, 118, 325		97.296.805	61,302,565	11.854	3,877,873				0	0	0		0
	•	200, 118,323	6,308,444	97,290,800		11,804				,	0	0	0	23,904,820	0
21.	Increase in reserves for accident and health contracts	0	0	0	0	0	0	0	1		0	0	0	0	XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	Total underwriting deductions (Lines 17 to 22)	2,535,185,011	88.304.368	1,289,455,840	463,777,634	1.097.816	34 . 198 . 097		(0	0	0	0	331.133.260	0
24.	Net underwriting gain or (loss) (Line 7 minus Line	2,000, 100,011		1,200, 100,010				027 ,217 ,000		,					
	23) DETAILS OF WRITE-INS	86,645,085	5,432,383	58,876,663	(2,112,099)	97,002	1,477,597	933,915	(0	0	0	0	21,939,624	0
0501.	DETAILS OF WRITE-INS														xxx
0501.															
0502.															
0598.	Summary of remaining write-ins for Line 5 from														
0330.	overflow page	0	0	0	0	0	0	0	lo	0	0	0	0	0	XXX
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
0601.	above)	Ü	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	7000
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
1301.	45010)		7000	7000	////	////	///X	7000	7000	7000	7000	7000	7000	7000	XXX
1301.				•••••	• • • • • • • • • • • • • • • • • • • •										XXX
1302.															XXX
1398.	Summary of remaining write-ins for Line 13 from overflow page	٥	n	n	۸	0	Λ	n	0	0	0	n	n	n	XXX
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13														
	above)	0	0	0	0	0	0	0	0	0	0	0	0	0	XXX

7

_

ANNUAL STATEMENT FOR THE YEAR 2023 OF THE Wellmark, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMILIMS

PART 1 - PREMIUMS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
Comprehensive (hospital and medical) individual		0	0	93,668,300
Comprehensive (hospital and medical) group		0	0	1,351,105,528
3. Medicare Supplement	461,646,882	0	0	461,646,882
4. Vision only	1,194,818	0	0	1, 194,818
5. Dental only		0	0	35,679,803
6. Federal Employees Health Benefits Plan	319,649,085	0	0	319,649,085
7. Title XVIII - Medicare	0	0	0	0
8. Title XIX - Medicaid	0	0	0	0
9. Credit A&H	0	0	0	0
10. Disability Income	0	0	0	0
11. Long-Term Care	0	0	0	0
12. Other health	352,234,996	0	0	352,234,996
13. Health subtotal (Lines 1 through 12)	2,615,179,412	0	0	2,615,179,412
14. Life	0	0	0	0
15. Property/casualty	0	0	0	0
16. Totals (Lines 13 to 15)	2,615,179,412	0	0	2,615,179,412

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

Comprehensive A S S F R S D D D D D D D D D			PART 2 - CLAIMS		· ·				
1. Payments during the year	7	6	5	4			1		
Popular Suffing the year									
1) Direct	Health	Dental Only	Vision Only		Group	Individual	Total		
1 2 Reinsurance assistmed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0					,			ments during the year:	1.
1 3 Reinsurance ceded	74300,977,07	28,864,774	940,835	393,203,956	1, 136, 861, 220	77,967,661	2,228,794,400	Direct	
1.4 Net	0	0	0	0	0	0	0	Reinsurance assumed	
2. Paid medical incentive pools and boruses			0	0				Reinsurance ceded	
2. Paid medical incentive pools and bonuses. 3. Claim liability December 31, current year from Part 22: 3. 1 Direct 3. 2 Reinsurance assumed. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0. 0	74300,977,07	28,864,774	940,835	393,203,956	1, 136, 861, 220	77,967,661	2,228,794,400	Net	
3. Claim liability December 31, current year from Part 2A: 3.1 Direct. 3.1 Direct. 3.2 Rensurance assumed. 0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0								d medical incentive pools and	2.
## from Part 2A: 3.1 Direct		0	0	0 .	12,363,794	835,486	13, 199, 280	nuses	
3.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0								om Part 2A:	
3.3 Reinsurance ceded		1,570,373	29,501	59,170,000	117,135,512	7,800,000	236,281,742	Direct	
3.4 Net		0	0 .	0 .	0			Reinsurance assumed	
4. Claim reserve December 31, current year row Part 2D: 4.1 Direct 4.2 Reinsurance assumed 5. A Crued medical incentive pools and bonuses, current year 6. Net health care receivables (a) 7. Amounts recoverable from reinsures 7. December 31, current year 8. December 31, current year 8. December 31, current year 8. Reinsurance ceded 9. Claim liability December 31, prior year from Part 2D: 8. Reinsurance ceded 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year	0	0	0	0 .	0	0	0	Reinsurance ceded	
year from Part 2D: 4.1 Direct	373 24,046,00	1,570,373	29,501	59,170,000 .	117, 135, 512	7,800,000	236,281,742	Net	
4.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0								ar from Part 2D:	
4.3 Reinsurance ceded		0	0	0	0	0			
4.4 Net	•			0		0			
5. Accrued medical incentive pools and bonuses, current year and control pools and bonuses, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Claim reserve December 31, prior year from Part 2D: 9. Sa Reinsurance deed and and an analysis and control pools and bonuses, prior year and and control pools and bonuses, prior year and and control pools and bonuses, prior year and and an analysis and analysis analysis and analysis analysis and analysis and analysis and analysis analysis and analysis analysis and analysis	0			0 .					
bonuses, current year	0	0	0 .	0 .	0	0	0		
7. Amounts recoverable from reinsurers December 31, current year 8. Claim liability December 31, prior year from Part 2A: 8.1 Direct 8.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0	0	0	0				nuses, current year	
December 31, current year	0 30,97	0	0	156,586	(15,518,016)	(1,931,183)	(15,457,699)	health care receivables (a)	6.
8. Claim liability December 31, prior year from Part 2A: 8.1 Direct									7.
8.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		0	0	0	0	0	0	im liability December 31, prior year	8.
8.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	81 24,109,00	1,666,381	34,529	62,425,000	120,946,809	8,062,000	244,260,586	Direct	
8.3 Reinsurance ceded 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0								Reinsurance assumed	
9. Claim reserve December 31, prior year from Part 2D: 9.1 Direct	0	0	0	0	0	0	0	Reinsurance ceded	
9. Claim reserve December 31, prior year from Part 2D: 9.1 Direct	81 24,109,00	1,666,381	34,529	62,425,000	120,946,809	8,062,000	244,260,586	Net	
9.2 Reinsurance assumed 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		, ,	,	, ,				im reserve December 31, prior year om Part 2D:	9.
9.3 Reinsurance ceded		0	0	0 .	0 .	0 .			
9.4 Net	•			0 .	0 .	0 .			
10. Accrued medical incentive pools and bonuses, prior year	0	0		0 .	0 .	0 .			
bonuses, prior year		0	0	0 .	0	0 .	0		
	0	0	0	0	3,878,101	232,453	4,110,554		10.
December 31, prior year	0	0	0	0	0	0	0	ounts recoverable from reinsurers ecember 31, prior year	11.
12. Incurred Benefits:								urred Benefits:	12.
12.1 Direct	66300,883,10	28,768,766	935,807	389,792,370	1,148,567,939	79,636,844	2,236,273,255	1 Direct	
12.2 Reinsurance assumed00000000000000		0	0	0	0	0 .	0	2 Reinsurance assumed	
12.3 Reinsurance ceded	•	U	0	0	0	0	0	3 Reinsurance ceded	
12.4 Net	66 300,883,10	28,768,766	935,807	389,792,370	1,148,567,939	79,636,844	2,236,273,255	4 Net	
13. Incurred medical incentive pools and bonuses 12,498,726 860,829 11,637,897 0 0 0 0 0 0 0 0 0 0 0									13.

⁽a) Excludes \$0 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

					FAN		LIADILITI ENL	OF CURREN							
		1	Compre	hensive	4	5	6	7	8	9	10	11	12	13	14
			(Hospital 8												
			2	3				Federal Employees							
					Medicare			Health	Title XVIII	Title XIX		Disability	Long-Term		Other
		Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
1 R	eported in Process of Adjustment:			·		•	•								
		74 040 700	0.000.070	04 770 404	00 000 155	Г 000	014 075	F 700 000	0	0	0	0	0	7.338.661	
	1 Direct	71,342,763		31,770,191	, ,		314,075	, ,	0	0	U	U	0		0
1.	2 Reinsurance assumed	0	0				0	0	0	0	0	0	0	0	0
1.	3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1.	4 Net	71,342,763	2.263.878		23,929,155	5.900	314.075	5,720,903	0	0	0	0	0	7.338.661	l 0
		, , , ,	, -,	, , ,	1,1 1,	-,-	,	, , , , , ,						, ,	
2. In	curred but Unreported:														
2.	1 Direct	164,938,979	5 , 536 , 122	85,365,321	35,240,845	23,601	1,256,298	18,325,097	0	0	0	0	0	19,191,695	0
2.	2 Reinsurance assumed	0	0	0	0	0	0	0			0	0	0	0	0
2.	3 Reinsurance ceded	0	0	0	0				0	0	0	0	0	0	0
	4 Net		5,536,122			23.601			0				0	19 . 191 . 695	
2.	4 Net	104,930,979	,,3,300, 122	65 , 565 , 52 1		23,001	1,230,230	10,023,097		U	0		0	13, 131,033	
3. A	mounts Withheld from Paid Claims														
	and Capitations:														
3	1 Direct	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0		0	0	0
													0		
3.	3 Reinsurance ceded	0	0	0	0		0	0	0	0	0	0	0	0	0
3.	4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4. T	OTALS:														1
		006 004 740	7 000 000	117 105 510	EO 170 000	20 504	1 570 070	04 046 000		0		0	0	06 500 050	
	1 Direct	236,281,742			59,170,000							0	0	26,530,356	0
	2 Reinsurance assumed		0	0	0	0	0	0	0	0	0	0	0	0	0
4.	3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.	4 Net	236,281,742	7,800,000	117, 135, 512	59,170,000	29,501	1,570,373	24,046,000	0	0	0	0	0	26,530,356	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRICE			Claim Reserve a		5	6
	Claims Paid D	uring the Year	December 31 o	of Current Year	-	Estimated Claim
	l l	2	3	4		Reserve and Claim
	On Claims Incurred		On Claims Unpaid		Claims Incurred	Liability
	Prior to January 1	On Claims Incurred	December 31 of	On Claims Incurred	In Prior Years	December 31 of
Line of Business	of Current Year	During the Year	Prior Year	During the Year	(Columns 1 + 3)	Prior Year
Comprehensive (hospital and medical) individual	6,407,078	71,560,583	59,847	7,740,153	6,466,925	8,062,000
Comprehensive (hospital and medical) group	106,802,783	1,030,058,437	836,542	116,298,970	107,639,325	120,946,809
3. Medicare Supplement	51,269,415	341,934,541	74,899	59,095,101	51,344,314	62,425,000
4. Vision Only		906,976	670	28,831	34,529	34,529
5. Dental Only	1,427,671	27,437,103	35,686	1,534,687	1,463,357	1,666,381
6. Federal Employees Health Benefits Plan	22,825,794	278 , 151 , 283	651,814	23,394,186	23,477,608	24,109,000
7. Title XVIII - Medicare	0	0	0	0	0	0
8 Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	24,739,990	265,238,887	252,548	26,277,808	24,992,538	27,016,867
13. Health subtotal (Lines 1 to 12)	213,506,590	2,015,287,810	1,912,006	234,369,736	215,418,596	244,260,586
14. Health care receivables (a)		68,471,619	4,084	543,326	31,669,114	116,141,758
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts		11,435,000	0	3,410,000	1,764,280	4,110,554
17. Totals (Lines 13 - 14 + 15 + 16)	183,605,840	1,958,251,191	1,907,922	237,236,410	185,513,762	132,229,382

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		•	Cum	nulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1.	Prior	214,688	215,147	215, 147	215, 147	215,147
2.	2019	1,099,532	1,315,927	1,315,275	1,315,275	1,315,275
3.	2020	XXX	1,057,547	1,254,477	1,254,112	1,254,112
4.	2021	XXX	XXX	1,072,179	1,293,725	1,295,107
5.	2022	XXX	XXX	XXX	1,133,410	1,248,243
6.	2023	XXX	XXX	XXX	XXX	1,111,815

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

		Sum of Cumulative N	et Amount Paid and Claim Outs	n Liability, Claim Rese standing at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses			
	Year in Which Losses Were Incurred	1 2 3 4 2019 2020 2021 2022							
1.	Prior	216,600	215, 147	215, 147	215,147	215, 147			
2.	2019	1,342,459	1,317,449	1,315,275	1,315,275	1,315,275			
3.	2020	XXX	1,274,806	1,255,114	1,254,112	1,254,112			
4.	2021	XXX	XXX	1,307,427	1,294,225	1,295,151			
5.	2022	XXX	XXX	XXX	1,266,030	1,249,094			
6.	2023	XXX	XXX	XXX	XXX	1,239,264			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019		1,315,275	26,665	2.0	1,341,940	86.0	0	0	1,341,940	86.0
2.	2020		1,254,112	16,269	1.3	1,270,381	85.7	0	0	1,270,381	85.7
3.	2021		1,295,107	22,553	1.7	1,317,660	90.7	44	0	1,317,704	90.7
4.	2022		1,248,243	21, 136	1.7	1,269,379	87.6	851	14	1,270,244	87.7
5.	2023	1,442,069	1,111,815	31,420	2.8	1,143,235	79.3	127,449	2,031	1,272,715	88.3

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

			Cum	nulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1.	Prior	60,622	60,675	60,675	60,675	60,675
2.	2019	296,262		365,229		
3.	2020	XXX	280,791	345,076	345,247	345,247
4.	2021	XXX	XXX	300,240	374,948	375, 128
5.	2022	XXX	XXX	XXX	330,862	
6.	2023	XXX	XXX	XXX	XXX	341,935

Section B - Incurred Health Claims - Medicare Supplement

•	Sum of Cumulative Net	Amount Paid and Claim Outs	Liability, Claim Resetanding at End of Yea	erve and Medical Incenti ar	ve Pool and Bonuses		
	1 2 3 4						
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023		
1. Prior		60,675	60,675	60,675	60,675		
2. 2019		365 , 184	365,229				
3. 2020	XXX	357,704	345,213	345,247	345,247		
4. 2021	XXX	XXX	386,010	375,019	375 , 129		
5. 2022	XXX	XXX	XXX	393,216	382,025		
6. 2023	XXX	XXX	XXX	XXX	401,030		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	420,477		15,088	4.1	380,317	90.4	0	0	380,317	90.4
2.	2020	425, 168	345,247	15,224	4.4	360,471	84.8	0	0	360,471	84.8
3.	2021		375, 128	14,530	3.9		87.0	1	0		87.0
4.	2022	458, 152	381,951	12,613	3.3		86.1	74	1	394,639	86.1
5.	2023	461,665	341,935	11,742	3.4	353,677	76.6	59,095	941	413,713	89.6

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Dental Only

			Cur	mulative Net Amounts F	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1.	Prior	1,479	1,490	1,490	1,490	1,490
2.	2019	22,546	23,742	23,754	23,754	23,754
3.	2020	XXX	19,748	21,192	21,246	21,246
4.	2021	XXX	XXX	24,943	26,328	26,356
5.	2022	XXX	XXX	XXX	25,939	27,338
6.	2023	XXX	XXX	XXX	XXX	27,437

Section B - Incurred Health Claims - Dental Only

Goodion B initiativa noutri Gianno Bontar Giny					
	Sum of Cumulative N	et Amount Paid and Clair Out	n Liability, Claim Rese standing at End of Yea	rve and Medical Incentivar	e Pool and Bonuses
	1	5			
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	1,483	1,490	1,490	1,490	1,490
2. 2019	24,260	23,749	23,754	23,754	23,754
3. 2020	XXX	21,525	21,215	21,246	21,246
4. 2021	XXX	XXX	26,683	26,364	
5. 2022	XXX	XXX	XXX	27,569	27,374
6. 2023	XXX	XXX	XXX	XXX	28,972

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	30,356	23,754	1,177	5.0	24,931	82.1	0	0	24,931	82.1
2.	2020	31,989	21,246	1,457	6.9	22,703	71.0	0	0	22,703	71.0
3.	2021		26,356	1,233	4.7	27,589	84.8	0	0	27,589	84.8
4.	2022		27,338	1,221	4.5	28,559	84.0	36	1	28,596	84.1
5.	2023	35,676	27,437	1,528	5.6	28,965	81.2	1,535	24	30,524	85.6

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Vision Only

		Cur	mulative Net Amounts F	aid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	21	21	21	21	21
2. 2019	783	805	805	805	805
3. 2020	XXX	658	683	684	684
4. 2021	XXX	XXX	793	818	819
5. 2022	XXX	XXX	XXX	849	882
6. 2023	XXX	XXX	XXX	XXX	907

Section B - Incurred Health Claims - Vision Only

	Sum of Cumulative Net	Amount Paid and Claim Outs	Liability, Claim Rese tanding at End of Yea	rve and Medical Incenti ar	ve Pool and Bonuses		
	1 2 3 4						
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023		
1. Prior	21	21	21	21	21		
2. 2019	805	805	805	805	805		
3. 2020	XXX	683	683	684	684		
4. 2021	XXX	XXX	819	819	819		
5. 2022	XXX	XXX	XXX	883	883		
6. 2023	XXX	XXX	XXX	XXX	936		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	1,021	805	84	10.4	889	87.1	0	0		87.1
2.	2020	1.017	684	122	17.8	806	79.3	0	0	806	79.3
3.	2021	1.092	819	95	11.6	914	83.7	0	0	914	83.7
4.	2022	1.131	882	115	13.0	997	88.2	1	0	998	88.2
5.	2023	1,195	907	150	16.5	1,057	88.5	29	0	1,086	90.9

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023	
1.	Prior	28,542	28,791	28,791	28,791	28,791	
2.	2019	204,426	241,734	242,006	242,006	242,006	
3.	2020	XXX	215,143	247,113	247,267	247,267	
4.	2021	XXX	XXX	231,942	274,478	275, 118	
5.	2022	XXX	XXX	XXX	247, 128	269,314	
6.	2023	XXX	XXX	XXX	XXX	278, 151	

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

			et Amount Paid and Claim Outs	Liability, Claim Rese standing at End of Ye	erve and Medical Incentivar	e Pool and Bonuses
	Year in Which Losses Were Incurred	1 2019	2 2020	3 2021	4 2022	5 2023
1.	Prior	28,791	28,791	28,791	28,791	28,791
2.	2019	237,405	242,379	242,006	242,006	242,006
3.	2020	XXX	251,503	247,532	247,267	247,267
4.	2021	XXX	XXX	274,530	274,701	275 , 138
5.	2022	XXX	XXX	XXX	271,014	269,946
6.	2023	XXX	XXX	XXX	XXX	301,545

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2019	260,409	242,006	16, 164	6.7		99.1	0	0	258 , 170	99.1
2	2020	287,201	247,267	19, 165	7.8		92.8	0	0		92.8
3	2021	292,734	275, 118	17,036	6.2		99.8	20	0		99.8
4	2022		269,314	16,649	6.2		96.8	632	17	286,612	97.0
5	2023	328, 152	278, 151	18,311	6.6	296,462	90.3	23,394	608	320,464	97.7

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted) Section A - Paid Health Claims - Other

			Cur	nulative Net Amounts P	aid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior		20,273	20,273	20,274	20,274	20,274
2. 2019		244,761	267,076	267,076	267,076	267,076
3. 2020		XXX	270, 189	288,076	288,076	288,076
4. 2021		XXX	XXX	241, 114	260,480	260,480
5. 2022		XXX	XXX	XXX	291,356	316,096
6. 2023		xxx	XXX	XXX	XXX	265,239

Section B - Incurred Health Claims - Other

	Sum of Cumulative Net	Amount Paid and Claim Outs	n Liability, Claim Rese standing at End of Ye	erve and Medical Incention	ve Pool and Bonuses
Year in Which Losses Were Incurred	1 2019	2 2020	3 2021	4 2022	5 2023
1. Prior	20,434	20,273	20,274	20,274	20,274
2. 2019	268,772	267,231	267,076	267,076	267,076
3. 2020	XXX	290,399	288,204	288,076	288,076
4. 2021	XXX	XXX	262,375	260,653	260,481
5. 2022	XXX	XXX	XXX	318,200	316,348
6. 2023	XXX	XXX	XXX	XXX	291,517

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2019	287,424	267,076	16,431	6.2	283,507	98.6	0	0	283,507	98.6
2.	2020	306,322	288,076	16,803	5.8	304,879	99.5	0	0	304,879	99.5
3.	2021	324,897	260,480	12,892	4.9	273,372	84.1	1	0	273,373	84.1
4.	2022	332,915	316,096	7,983	2.5	324,079	97.3	252	4	324,335	97.4
5.	2023	353,073	265,239	10,059	3.8	275,298	78.0	26,278	418	301,994	85.5

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cu	imulative Net Amounts F	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior		326,397	326,398	326,398	326,398
2. 2019	1,868,310	2,214,404	2,214,145	2,214,145	2,214,145
3. 2020	XXX		2,156,617	2,156,632	2,156,632
4. 2021	XXX	xxx	1,871,211	2,230,777	2,233,008
5. 2022	XXX	xxx	xxx	2,029,544	2,243,824
6. 2023	XXX	XXX	XXX	XXX	2,025,484

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net A	mount Paid and Claim Outs	Liability, Claim Rese standing at End of Ye	erve and Medical Incention	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2019	2020	2021	2022	2023
1. Prior	328,098	326,397	326,398	326,398	326,398
2. 2019	2,241,206	2,216,797	2,214,145	2,214,145	2,214,145
3. 2020	XXX	2,196,620	2,157,961	2,156,632	2,156,632
4. 2021	XXX	XXX	2,257,844	2,231,781	2,233,074
5. 2022	XXX	XXX	XXX	2,276,912	2,245,670
6. 2023	XXX	XXX	XXX	XXX	2,263,264

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
	Years in which					Claim and Claim Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
	Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1.	2019	2,560,223	2,214,145	75,609	3.4	2,289,754	89.4	0	0	2,289,754	89.4
2.	2020	2,534,132	2,156,632	69,040	3.2	2,225,672	87.8	0	0	2,225,672	87.8
3.	2021	2,551,896	2,233,008		3.1	2,301,347	90.2	66	0	2,301,413	90.2
4.	2022	2,570,575	2,243,824	59,717	2.7	2,303,541	89.6	1,846	37	2,305,424	89.7
5.	2023	2,621,830	2,025,484	73,210	3.6	2,098,694	80.0	237,780	4,022	2,340,496	89.3

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY													
		1	Compreh		4	5	6	7	8	9	10	11	12	13
			(Hospital &	Medical)	-			Federal						
			-	· ·				Employees						
		Total	Individual	Group	Medicare Supplement	Vision Only	Dental Only	Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
	Unearned premium reserves					,	ĺ	İ						Other
1.	•	71,849	(66,238)	157,274			· ·		0	0	0	0	0	0
2.	Additional policy reserves (a)	0	0	0	0	0	0	0	0	0	0	0	0	0
3.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0	0	0	0 .	0
4.	Reserve for rate credits or experience rating refunds													
	(including \$0 for investment income)	62,723,129	0	29,278,375	0	0	0	33,444,754	0	0	0	0	0	0
5.	Aggregate write-ins for other policy reserves	1,715,000	0	1,715,000	0	0	0	0	0	0	0	0	0	0
6.	Totals (gross)	64,509,978	(66,238)	31, 150, 649	(23,296)	0	4,109	33,444,754	0	0	0	0	0	0
7.	Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0
8.	Totals (Net)(Page 3, Line 4)	64,509,978	(66,238)	31, 150, 649	(23,296)	0	4,109	33,444,754	0	0	0	0	0	0
9.	Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0	0	0	0	0
10.	Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0	0	0	0	0
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0	0	0	0	0		0	0		0	0	0
13.	Reinsurance ceded	0	0	0	0	0	0		0	0	0	0	0	0
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS													
0501.	ACA Risk Adjustment Payable	1,715,000	0	1,715,000	0	0	0	0	0	0	0	0	0	0
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	1,715,000	0	1,715,000	0	0	0	0	0	0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$ ______ 0 premium deficiency reserve.

EXHIBIT OF NET INVESTMENT INCOME

		1	2
	HO	Collected During Year	
1.	U.S. government bonds		
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)	. , , , , , , , , , , , , , , , , , , ,	44,000,6
1.3	Bonds of affiliates		
2.1	Preferred stocks (unaffiliated)	(-)	59,3
2.11	Preferred stocks of affiliates		
2.2	Common stocks (unaffiliated)		, - ,
2.21	Common stocks of affiliates		
3.	Mortgage loans		
4.	Real estate		13,475,0
5	Contract Loans		
6	Cash, cash equivalents and short-term investments		
7	Derivative instruments		
8.	Other invested assets		7,909,4
9.	Aggregate write-ins for investment income	,	747,8
10.	Total gross investment income	202,875,714	204,799,
11.	Investment expenses		
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		
15.	Aggregate write-ins for deductions from investment income		
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		192,450,5
	DETAILS OF WRITE-INS		
901.	Miscellaneous Investment Income	747,807	747,8
902.			
903.			
998.	Summary of remaining write-ins for Line 9 from overflow page	0	
999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	747,807	747,8
501.			
502.			
503.			
598.	Summary of remaining write-ins for Line 15 from overflow page		
599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		

(a) Includes \$	11,144,139	accrual of discount less \$13,231,802	amortization of premium and less $\$$	1,658,572	paid for accrued interest on purchases.
(b) Includes \$	0	accrual of discount less \$ 0	amortization of premium and less \$	0	paid for accrued dividends on purchases
(c) Includes \$	0	accrual of discount less \$ 0	amortization of premium and less \$	0	paid for accrued interest on purchases.
(d) Includes \$	13,475,025	for company's occupancy of its own building	s; and excludes \$ 0 in	nterest on encum	nbrances.
(e) Includes \$	2,394,686	accrual of discount less \$461,948	amortization of premium and less \$	4,690	paid for accrued interest on purchases.
(f) Includes \$	0	accrual of discount less \$ 0	amortization of premium.		
	0 and Separate Acco	investment expenses and \$.0 investment taxes, licenses and fees,	, excluding feder	ral income taxes, attributable to
(h) Includes \$	0	interest on surplus notes and \$	0 interest on capital notes.		
(i) Includes \$	6 434 853	depreciation on real estate and \$	depreciation on other invested	accete	

EXHIBIT OF CAPITAL GAINS (LOSSES)

	EVUIDIT	OF CAPI	IAL GAIN	⊙ (LU 33⊏	.3)	
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	(1.134.960)	0	(1.134.960)	0	0
1.1	Bonds exempt from U.S. tax	0	0	0	0	0
1.2	Other bonds (unaffiliated)	(9,959,811)	(1,158,323)	(11, 118, 134)	1,231,521	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	31,506	(120,710)	(89,204)	417,810	184,417
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)					
2.21	Common stocks of affiliates	0	0	0	40,401,352	0
3.	Mortgage loans	0	0	0	0	
4.	Real estate	0	0	0	0	0
5.	Contract loans	0	0	0	0	0
6.	Cash, cash equivalents and short-term investments	(45,169)	(209,323)	(254,492)	0	0
7.	Derivative instruments	0	0	0	0	0
8.	Other invested assets	(4,781)	(450,000)	(454,781)	(4,232,817)	0
9.	Aggregate write-ins for capital gains (losses)	0			0	0
10.	Total capital gains (losses)	20,017,827	(13,635,788)	6,382,039	112,328,887	8,022,074
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	0	0	0	0	0

EXHIBIT OF NON-ADMITTED ASSETS

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)		0	0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks	552 485	908 147	355 662
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			(1, 100, 100,
0.	3.1 First liens	0	0	0
	3.2 Other than first liens			
4.	Real estate (Schedule A):			
٦.	4.1 Properties occupied by the company	27 424 760	32 853 757	5 428 997
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			
7.	Derivatives (Schedule DB)			
8.	Other invested assets (Schedule BA)			
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:			
10.	15.1 Uncollected premiums and agents' balances in the course of collection	0	0	0
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
10.	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
47	Amounts receivable relating to uninsured plans			
			0	_
	Current federal and foreign income tax recoverable and interest thereon Net deferred tax asset			0
	Guaranty funds receivable or on deposit		0	
19.			5,216,863	
20.	Electronic data processing equipment and software			
21.	Furniture and equipment, including health care delivery assets			
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivable from parent, subsidiaries and affiliates		10,725,607	
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other than invested assets		51,211,350	(13,308,573)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)		272,342,933	
27.		275, 150, 111	272,342,933	
28.	Total (Lines 26 and 27)	275, 150, 111	212,342,933	(2,807,178)
1101.	DETAILS OF WRITE-INS			
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Premium Tax Assets	13,891,586	16,314,323	2,422,737
2502.	Prepaid Pension Costs	24,763,757	12,465,891	(12,297,866)
2503.	Other Prepaid Expenses	24,438,685	20,907,928	(3,530,757
2598.	Summary of remaining write-ins for Line 25 from overflow page	1,425,895	1,523,208	97,313
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	64,519,923	51,211,350	(13,308,573)

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

		Total Members at End of							
		1	2	3	4	5	Current Year		
	Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months		
1.	Health Maintenance Organizations	0	0	0	0	0	0		
2.	Provider Service Organizations	0	0	0	0	0	0		
3.	Preferred Provider Organizations	808,894	804,637	801,398	798,580	800,390	9,626,029		
4.	Point of Service	0	0	0	0 .	0	0		
5.	Indemnity Only	165,897	160,518	159,812	159,464	158,440	1,918,558		
6.	Aggregate write-ins for other lines of business.	157,543	167,622	168,050	168,903	169,806	2,021,318		
7.	Total	1,132,334	1,132,777	1,129,260	1,126,947	1,128,636	13,565,905		
	DETAILS OF WRITE-INS								
0601.	Dental	98,295	99,895	100,305	100,709	101,585	1,204,573		
0602.	Medicare Part D	47,496	55,465	55,261	55,569	55,522	667 , 125		
0603.	Vision	11,752	12,262	12,484	12,625	12,699	149,620		
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0		
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	157,543	167,622	168,050	168,903	169,806	2,021,318		

NOTE 1 Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The financial statements of Wellmark, Inc. (the Company) have been prepared in conformity with the accounting practices prescribed by the National Association of Insurance Commissioners (NAIC) and the State of Iowa.

The NAIC Accounting Practices and Procedures manual has been adopted as a component of prescribed or permitted practices by the State of lowa. The Commissioner of Insurance has the right to permit specific practices that deviate from prescribed practices. The Company does not have any permitted practices.

			F/S	F/S		
		SSAP#	Page	Line #	 2023	 2022
NE (1)	ET INCOME) State basis (Page 4, Line 32, Columns 2 & 3)	XXX	xxx	XXX	\$ 216,533,140	\$ 82,368,021
(2)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(3)) State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(4)) NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 216,533,140	\$ 82,368,021
SI	JRPLUS					
(5)		XXX	XXX	XXX	\$ 2,640,534,685	\$ 2,280,781,796
(6)) State Prescribed Practices that are an increase/(decrease) from NAIC SAP:					
(7)	State Permitted Practices that are an increase/(decrease) from NAIC SAP:					
(8)) NAIC SAP (5-6-7=8)	xxx	XXX	XXX	\$ 2,640,534,685	\$ 2,280,781,796

B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those estimates.

C. Accounting Policy

Premiums on fully insured accident and health plans are billed in advance of their respective coverage periods. Receivables and income for such premiums are recorded at the effective date of the coverage period. Premiums received in advance and any unearned portion of premiums are recorded on the balance sheets as premiums received in advance and unearned premiums and reported as income when earned.

Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. Other costs, such as premium taxes and other underwriting expenses, are also charged to operations as incurred.

Real estate is carried at depreciated cost, less encumbrances. The fair value of real estate owned is determined by an external appraisal. To the extent the depreciated cost exceeds the fair value, this excess has been nonadmitted.

In addition, the Company uses the following accounting policies:

(1) Basis for Short-Term Investments

Short-term investments that are NAIC designation 1 or 2 are reported at cost adjusted for amortization of premiums and accretion of discounts using the effective interest method. Short-term investments that are NAIC designation 3 through 6 are stated at the lower of amortized cost or fair value.

(2) Basis for Bonds and Amortization Method

Bonds that are NAIC designation 1 or 2 are reported at cost adjusted for amortization of premiums and accretion of discounts using the effective interest method. Bonds that are NAIC designation 3 through 6 are stated at the lower of amortized cost or fair value. When a decline in the fair value of a bond has been determined to be other than temporary, the Company evaluates whether the decline is interest or credit related. For those credit-related declines in value that are considered to be other than temporary, the bond's carrying value is reduced and a loss is realized on the Statement of Revenues and Expenses. Surplus notes that are rated by an NAIC credit rating provider and have an NAIC designation of 1 are reported at cost, adjusted for amortization of premiums and accretion of discounts using the effective interest method.

The Company does not own any mandatory convertible securities or SVO-Identified Investments identified in SSAP No. 26R.

(3) Basis for Common Stocks

Unaffiliated common stocks are reported at fair value. When a decline in the fair value of an unaffiliated common stock is considered to be other than temporary, the book value of the stock is reduced to fair value and a loss is realized on the Statement of Revenues and Expenses.

(4) Basis for Preferred Stocks

Preferred stock is reported based on the underlying characteristics of the security (redeemable or perpetual) and the quality rating of the security expressed as an NAIC designation. When a decline in the fair value of a preferred stock is considered other than temporary, the book value of the stock is reduced to fair value and a loss is realized on the Statement of Revenues and Expenses.

(5) Basis for Mortgage Loans

Not applicable

(6) Basis for Loan-Backed Securities and Adjustment Methodology

Loan-backed securities that are NAIC designation 1 or 2 are reported at cost adjusted for amortization of premiums and accretion of discounts using the effective interest method. For all securities except for interest only securities or securities where the yield had become negative, the amortization of premiums and accretion of discounts on loan-backed securities is adjusted quarterly using current estimated future cash flows, including any new prepayment assumptions, using the retrospective adjustment method. Interest only securities and securities where the yield had become negative are valued using the prospective method. Loan-backed securities are stated at the lower of amortized cost or fair value if they are NAIC designation 3 through 6.

(7) Accounting Policies for Investments in Subsidiaries, Controlled and Affiliated Entities

Common stock of the Company's insurance subsidiaries is carried based on the underlying statutory equity of the entities and is nonadmitted for those entities where statutory basis audited financial statements are not obtained. Common stock of the Company's non-insurance subsidiaries is carried based on the underlying GAAP equity of the entities and is nonadmitted for those entities where GAAP basis audited financial statements are not obtained. For any non-insurance subsidiaries in a retained deficit position, the carrying value is reported at \$0.

(8) Accounting Policies for Investments in Joint Ventures, Partnerships and Limited Liability Entities

The Company has ownership interest in an affiliated joint venture. This investment is in a downstream noninsurance holding company and the Company utilizes a look through approach to carry this investment at the underlying statutory equity of the insurance entity owned by the holding company. See Note #10 L.

The Company has minor ownership interests in two limited partnerships. The Company carries these interests based on the underlying audited GAAP equity of the investees.

The Company also has minor ownership interests in limited liability companies. These interests are carried based on the underlying GAAP equity of the investees and are nonadmitted for those investees where GAAP basis audited financial statements are not available.

(9) Accounting Policies for Derivatives

Not applicable

(10) Anticipated Investment Income Used in Premium Deficiency Calculation

The Company anticipates investment income as a factor in the premium deficiency calculation, in accordance with Statement of Statutory Accounting Principles (SSAP) 54, Individual and Group Accident and Health Contracts.

(11) Management's Policies and Methodologies for Estimating Liabilities for Losses and Loss/Claim Adjustment Expenses

The Company provides a liability for unpaid and unreported benefits, which represents the estimated ultimate cost of benefits incurred through the balance sheet date. The liability is estimated on the basis of past experience and accumulated statistical data. Subsequent actual benefit experience may differ from the estimated liability due to variances in estimated and actual utilization of health care services, the amount of charges and other factors. These estimates are continuously reviewed and, as adjustments become necessary, such adjustments are reflected in current operations.

(12) Changes in the Capitalization Policy and Predefined Thresholds from Prior Period

The Company has not modified its capitalization policy from the prior period.

(13) Method Used to Estimate Pharmaceutical Rebate Receivables

The Company estimates pharmaceutical rebates utilizing past experience and accumulated statistical data. These estimates are continuously reviewed, and any adjustments are reflected in current operations.

D. Going Concern

Management has evaluated the Company's ability to continue as a going concern and has concluded that there are no events or circumstances that raise any doubt about the Company's ability to continue as a going concern.

NOTE 2 Accounting Changes and Corrections of Errors

Not applicable

NOTE 3 Business Combinations and Goodwill

A. Statutory Purchase Method

Effective July 12, 2023, the Company acquired the remaining 50% ownership interest in Wellmark Value Health Plan, Inc. (WVHP), resulting in the Company owning 100% of the outstanding shares of WVHP. WVHP is licensed in the state of lowa, however as of January 1, 2021, WVHP no longer offered contracts for covered health care services.

The transaction was accounted for as a statutory purchase, and reflects the following:

1	2	3	4	5
Purchased Entity	Acquisition Date	Cost of Acquired Entity	Original Amount of Goodwill	Original Amount of Admitted Goodwill
Wellmark Value Health Plan, Inc.	07/12/2023	\$ 7,004,341	\$ -	\$ -
Total	XXX	\$ 7,004,341	\$ -	\$ -

1	6	7	8	9
Purchased Entity	Admitted Goodwill as of the Reporting Date	Amount of Goodwill Amortized During the Reporting Period	Book Value of SCA	Admitted Goodwill as a % of SCA BACV, Gross of Admitted Goodwill Col. 6/Col. 8
Wellmark Value Health Plan, Inc.	\$ -	\$ -	\$ 7,055,182	0.0%
Total	\$ -	\$ -	\$ 7,055,182	XXX

B. Statutory Merger

Not applicable

C. Assumption Reinsurance

Not applicable

D. Impairment Loss

Not applicable

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not applicable

NOTE 4 Discontinued Operations

Not applicable

NOTE 5 Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

Not applicable

B. Debt Restructuring

Not applicable

C. Reverse Mortgages

Not applicable

- D. Loan-Backed Securities
 - (1) Description of Sources Used to Determine Prepayment Assumptions

For fixed-rate agency mortgage-backed securities, prepayment speeds are calculated utilizing Mortgage Industry Advisory Corporation (MIAC) Mortgage Industry Medians (MIMs). MIMs are derived from a semi-monthly dealer-consensus survey of long-term prepayment projections. For other mortgage-backed, loan-backed, and structured securities, prepayment assumptions are utilized from Moody's Analytics. Moody's applies a flat economic credit model and utilizes a vector of multiple monthly speeds as opposed to a single speed for more robust projections. In instances where Moody's projections are not available, data from Refinitiv is used, which utilizes the median prepayment speed from contributors' models.

(2) Other-Than-Temporary Impairments

There were no loan-backed securities with a current period recognized other-than-temporary impairment (OTTI) classified on the basis for the OTTI as "Intent to sell" or "Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis."

(3) Recognized OTTI Securities

Loan-backed securities with a current period recognized other-than-temporary impairment, currently held by the Company, as the present value of cash flows expected to be collected is less than the amortized cost basis of the securities follows as of December 31, 2023:

1	B,	2 ook/Adjusted		3	4		5	6	7 Date of
		arrying Value			Recognized	A	Amortized Cost		Financial
	An	nortized Cost	Pr	esent Value of	Other-Than-	At	fter Other-Than-		Statement
		efore Current	Р	rojected Cash	Temporary		Temporary	Fair Value at	Where
CUSIP	F	Period OTTI		Flows	Impairment		Impairment	time of OTTI	Reported
12464Y-AB-5	\$	829,994	\$	760,284	\$ 69,710	\$	760,284	\$ 633,280	12/01/2023
362334-MF-8	\$	1,860,574	\$	1,443,549	\$ 417,025	\$	1,443,549	\$ 1,355,751	12/31/2023
55027Y-AD-0	\$	547,838	\$	475,820	\$ 72,018	\$	475,820	\$ 425,415	12/31/2023
30247D-AD-3	\$	598,515	\$	511,646	\$ 86,869	\$	511,646	\$ 467,096	12/01/2023
933631-AD-5	\$	332,403	\$	265,835	\$ 66,568	\$	265,835	\$ 250,993	12/01/2023
45661E-AV-6	\$	422,410	\$	367,015	\$ 55,395	\$	367,015	\$ 333,145	12/31/2023
52521R-BP-5	\$	622,142	\$	572,086	\$ 50,056	\$	572,086	\$ 574,600	12/31/2023
32053E-AA-6	\$	113,212	\$	60,306	\$ 52,906	\$	60,306	\$ 60,306	12/01/2023
45661X-AB-8	\$	1,659,260	\$	1,531,003	\$ 128,257	\$	1,531,003	\$ 1,326,761	12/01/2023
52522D-AM-3	\$	817,894	\$	713,730	\$ 104,164	\$	713,730	\$ 615,346	12/01/2023
78445F-AE-5	\$	780,920	\$	725,565	\$ 55,355	\$	725,565	\$ 725,565	12/01/2023
Total		XXX		XXX	\$ 1,158,323		XXX	XXX	XXX

- (4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized interest related impairment remains):
 - a) The aggregate amount of unrealized losses:

1. Less than 12 Months \$ 11,670,088
2. 12 Months or Longer \$ 20,913,082

b) The aggregate related fair value of securities with unrealized losses:

 1. Less than 12 Months
 \$ 131,523,695

 2. 12 Months or Longer
 \$ 183,281,370

(5) Information Investor Considered in Reaching Conclusion that Impairments are Not Other-Than-Temporary

The unrealized losses on the Company's investments in loan-backed securities were due to temporary changes in interest rates and market conditions. The contractual cash flows of the agency mortgage-backed investments are guaranteed by an agency of the U.S. government and the non-agency mortgage-backed and asset-backed securities include collateral which reduce the risk of loss. Based on cash flow projections, the Company believes it will recover the carrying value of these investments. Because the Company does not have the intent to sell these securities, nor is it more likely than not the Company will be required to sell these securities until a recovery of carrying value, which may be maturity, the Company does not consider these investments to be other-than-temporarily impaired.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

Not applicable

- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing
 - (1) Company Policies or Strategies for Repo Programs

The Company participates in a repurchase agreement with Bankers Trust (the Bank). The repurchase agreement is an obligation of the Bank to repay the Company the principal amount invested by the Company with interest upon demand by the Company. To secure the obligations under the repurchase agreement, the Bank grants to the Company an undivided security interest in certain United States government securities having a market value equal to at least 102% of the principal amount invested. The United States government securities comprising the collateral are at all times owned by the Bank; therefore, this collateral was not recorded on the Company's statutory Balance Sheet. Since the repurchase agreement matures upon demand, there is no asset-liability mismatch.

(2) Type of Repo Trades Used

)

b. Tri-Party (YES/NO)

FIRST QUARTER	SECOND QUARTER	THIRD QUARTER	FOURTH QUARTER
Yes	Yes	Yes	Yes
No	No	No	No

(3) Original (Flow) & Residual Maturity

a. Maximum Amount
 Open – No Maturity
2. Overnight
3. 2 Days to 1 Week
4. > 1 Week to 1 Month
5. > 1 Month to 3 Months
6. > 3 Months to 1 Year
7. > 1 Year
b. Ending Balance
 Open – No Maturity

2. Overnight3. 2 Days to 1 Week4. > 1 Week to 1 Month5. > 1 Month to 3 Months6. > 3 Months to 1 Year

FIRST QUARTER			SECOND QUARTER	THIRD QUARTER		FOURTH QUARTER	
\$	43,813,744	\$	75,210,030	\$	55,419,481	\$	57,309,849
\$ \$	-	\$ \$	-	\$ \$	-	\$ \$	-
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-
\$	6,622,908	\$	5,923,892	\$	5,813,571	\$	7,589,867
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-
\$	-	\$	-	\$	-	\$	-

7. > 1 Year

(4) Fair Value Securities Sold and/or Acquired that Resulted in Default No securities were sold and/or acquired that resulted in default.

(5) Securities "Sold" Under Repo - Secured Borrowing

The Company deposits cash into an overnight sweep account. The Bank sweeps cash out of the Company's account and invests these funds into a Repurchase Agreement. The Company has not sold any securities as part of this agreement.

(6) Securities Sold Under Repo - Secured Borrowing by NAIC Designation

The Company deposits cash into an overnight sweep account. The Bank sweeps cash out of the Company's account and invests these funds into a Repurchase Agreement. The Company has not sold any securities as part of this agreement.

(7) Collateral Received – Secured Borrowing

a. Maximum Amount1. Cash2. Securities (FV)

b. Ending Balance 1. Cash

2. Securities (FV)

FIRST QUARTER			SECOND QUARTER		THIRD QUARTER	FOURTH QUARTER		
\$ \$	- 44,691,428	\$ \$	- 76,714,877	\$	56,528,260	\$	- 58,456,064	
\$ \$	- 6,755,602	\$ \$	- 6,042,587	\$ \$	- 5,930,441	\$ \$	- 7,743,007	

(8) Cash & Non-Cash Collateral Received - Secured Borrowing by NAIC Designation

ENDING BALANCE

- a. Cash
- b. Bonds FV
- c. LB & SS FV
- d. Preferred Stock FV
- e. Common Stock
- f. Mortgage Loans FV
- g. Real Estate FV
- h. Derivatives FV
- i. Other Invested Assets FV
- j. Total Collateral Assets FV (Sum of a through i)

1	2	3			4	
NONE	NAIC 1	NAIC 2		NAIC 3		
\$ -	\$ -	\$		\$		-
\$ -	\$ 7,743,007	\$	-	\$		-
\$ -	\$ -	\$	-	\$		-
\$ -	\$ -	\$	-	\$		-
\$ -	\$ -	\$	-	\$		-
\$ -	\$ -	\$	-	\$		-
\$ -	\$ -	\$	-	\$	-	-
\$ -	\$ -	\$	-	\$		-
\$ -	\$ -	\$	-	\$	-	-
\$ -	\$ 7,743,007	\$	-	\$		-

ENDING BALANCE

a. Cash
b. Bonds - FV
c. LB & SS - FV
d. Preferred Stock - FV
e. Common Stock
f. Mortgage Loans - FV
g. Real Estate - FV
h. Derivatives - FV
i. Other Invested Assets - FV
j. Total Collateral Assets - FV (Sum of a through i)

5 NAIC 4	6 NAIC 5	7 NAIC 6	8 DOES NOT QUALIFY AS ADMITTED
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -
\$ -	\$ -	\$ -	\$ -

- (9) Allocation of Aggregate Collateral by Remaining Contractual Maturity
 - a. Overnight and Continuous
 - b. 30 Days or Less
 - c. 31 to 90 Days
 - d. > 90 Days

F	AIR VALUE
\$	7,743,007
\$	-
\$	-
\$	-

(10) Allocation of Aggregate Collateral Reinvested by Remaining Contractual Maturity

The Bank holds the collateral for the benefit of the Company during the term of the repurchase agreement. The Company does not have any authority to reinvest the collateral.

(11) Liability to Return Collateral – Secured Borrowing (Total)

The Bank holds the collateral for the benefit of the Company during the term of the repurchase agreement. The Bank retains all rights of ownership in the collateral unless or until a default under the repurchase agreement. As a result, no liability has been recognized on the Company's Balance Sheet.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not applicable

H. Repurchase Agreements Transactions Accounted for as a Sale

Not applicable

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

Not applicable

J. Real Estate

Not applicable

K. Low Income Housing Tax Credits (LIHTC)

Not applicable

L. Restricted Assets

1. Restricted Assets (Including Pledged)

Restricted Asset Category	(A	1 otal Gross dmitted & Non- admitted) Restricted from Current Year	(2 Total Gross Admitted & Non- admitted) Restricted from Prior Year	(3 Increase/ Decrease) 1 minus 2)		4 Total Current Year Non- admitted Restricted		Total Current Year Admitted Restricted (1 minus 4)	6 Gross (Admitted & Non- admitted) Restricted to Total Assets (a)	7 Admitted Restricted to Total Admitted Assets (b)
Subject to contractual obligation for which liability is not shown	\$	-	\$	-	\$	-	\$	-	\$	-	0.000%	0.000%
b. Collateral held under security lending agreements c. Subject to repurchase agreements d. Subject to reverse repurchase agreements e. Subject to dollar repurchase agreements f. Subject to dollar reverse repurchase agreements g. Placed under option contracts h. Letter stock or securities restricted as to sale excluding FHLB capital stock i. FHLB capital stock	\$ \$ \$	7,589,867 - - - - - - 2,148,700	\$ \$ \$ \$	- 25,369,637 - - - - - - - - - -	\$ \$ \$ \$	- 17,779,770) - - - - - (2,079,000)	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		\$ \$ \$ \$ \$ \$ \$ \$	- 7,589,867 - - - - - - - - - - -	0.000% 0.181% 0.000% 0.000% 0.000% 0.000% 0.000%	0.000% 0.194% 0.000% 0.000% 0.000% 0.000%
j. On deposit with states	\$	-	\$	-	\$	-	\$	-	\$	-	0.000%	0.000%
k. On deposit with other regulatory bodies l. Pledged collateral to FHLB (including assets backing funding agreements) m. Pledged as collateral not captured in other categories n. Other restricted assets	\$ \$ \$	-	\$ \$ \$ \$	-	\$ \$ \$ \$	-	\$ \$ \$ \$ \$	-	\$ \$ \$	-	0.000% 0.000% 0.000% 0.000%	0.000% 0.000% 0.000% 0.000%
o. Total Restricted Assets (Sum of a through n)	ľ	9,738,567	·	29,597,337	ľ	19,858,770)		-		9,738,567	0.233%	0.249%

- (a) Column 1 divided by Asset Page, Column 1, Line 28
- (b) Column 5 divided by Asset Page, Column 3, Line 28
- 2. Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not applicable

- Detail of Other Restricted Assets (Contracts That Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)
 Not applicable
- 4. Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Not applicable

M. Working Capital Finance Investments

Not applicable

N. Offsetting and Netting of Assets and Liabilities

Not applicable

O. 5GI Securities

Not applicable

P. Short Sales

Not applicable

Q. Prepayment Penalty and Acceleration Fees

1. Number of CUSIPs 3. Aggregate Amount of Investment Income \$ 146,530

R. Reporting Entity's Share of Cash Pool by Asset Type

Not applicable

NOTE 6 Joint Ventures, Partnerships and Limited Liability Companies

A. Investments in Joint Ventures, Partnerships and Limited Liability Companies that Exceed 10% of Ownership

As of December 31, 2023, the Company has no investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10% of its admitted assets.

B. Investments in Impaired Joint Ventures, Partnerships and Limited Liability Companies

The Company did not recognize any impairment write down for its investments in Joint Ventures, Partnerships or Limited Liability Companies during 2023 or 2022.

NOTE 7 Investment Income

A. The basis, by category of investment income, for excluding (nonadmitting) any investment income due and accrued.

There was no amount of Investment Income due and accrued that was nonadmitted as of December 31, 2023.

B. The total amount excluded.

Not applicable

C. The gross, nonadmitted and admitted amounts for interest income due and accrued.

Interest Income Due and Accrued	 Amount
1. Gross	\$ 9,277,577
2. Nonadmitted	\$ -
3. Admitted	\$ 9,277,577

D. The aggregate deferred interest.

Not applicable

E. The cumulative amounts of paid-in-kind (PIK) interest included in the current principal balance.

Not applicable

NOTE 8 Derivative Instruments

Not applicable

NOTE 9 Income Taxes

- A. Deferred Tax Assets/(Liabilities)
 - 1. Components of Net Deferred Tax Asset/(Liability)

		2023			2022			Change	
	(1)	(2) (3) (Col. 1 + 2)		(4)	(4) (5)		(7) (Col. 1 - 4)	(8) (Col. 2 - 5)	(9) (Col. 7 + 8)
	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total
(a) Gross Deferred Tax Assets	\$ 80,036,000	\$ 28,432,000	\$ 108,468,000	\$ 67,541,000	\$ 20,701,000	\$ 88,242,000	\$ 12,495,000	\$ 7,731,000	\$ 20,226,000
(b) Statutory Valuation Allowance Adjustment (c) Adjusted Gross Deferred Tax Assets	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
(1a - 1b)	\$ 80,036,000	\$ 28,432,000	\$ 108,468,000	\$ 67,541,000	\$ 20,701,000	\$ 88,242,000	\$ 12,495,000	\$ 7,731,000	\$ 20,226,000
(d) Deferred Tax Assets Nonadmitted (e) Subtotal Net Admitted Deferred Tax Asset	\$ 11,689,000	\$ -	\$ 11,689,000	\$ 11,108,000	\$ -	\$ 11,108,000	\$ 581,000	\$ -	\$ 581,000
(1c - 1d)	\$ 68,347,000	\$ 28,432,000	\$ 96,779,000	\$ 56,433,000	\$ 20,701,000	\$ 77,134,000	\$ 11,914,000	\$ 7,731,000	\$ 19,645,000
(f) Deferred Tax Liabilities (g) Net Admitted Deferred Tax Asset/(Net	\$ 444,000	\$ 40,405,000	\$ 40,849,000	\$ 366,000	\$ 23,616,000	\$ 23,982,000	\$ 78,000	\$ 16,789,000	\$ 16,867,000
Deferred Tax Liability) (1e - 1f)	\$ 67,903,000	\$ (11,973,000)	\$ 55,930,000	\$ 56,067,000	\$ (2,915,000)	\$ 53,152,000	\$ 11,836,000	\$ (9,058,000)	\$ 2,778,000

2. Admission Calculation Components SSAP No. 101

· · · · · · · · · · · · · · · · · · ·	2023							2022			Change					
	(1)		(2)	((3) Col. 1 + 2)		(4)	(5)	((6) (Col. 4 + 5)	((7) Col. 1 - 4)	(1	(8) Col. 2 - 5)	((9) Col. 7 + 8)
	Ordinary		Capital	`	Total		Ordinary	Capital	,	Total		Ordinary [']	,	Capital	,	Total
(a) Federal Income Taxes Paid In Prior Years Recoverable Through Loss Carrybacks	\$ 42,135,000	\$	5,996,000	\$	48,131,000	\$	38,521,000	\$ 8,227,000	\$	46,748,000	\$	3,614,000	\$	(2,231,000)	\$	1,383,000
(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation (The Lesser of 2(b)1 and 2(b)2 Below)	\$ 7,799,000	\$	-	\$	7,799,000	\$	6,404,000	\$ -	\$	6,404,000	\$	1,395,000	\$	-	\$	1,395,000
Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date	\$ 7,799,000	\$	-	\$	7,799,000	\$	6,404,000	\$ -	\$	6,404,000	\$	1,395,000	\$		\$	1,395,000
Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold	xxx		XXX	\$	387,589,000		XXX	XXX	\$	333,126,000		XXX		xxx	\$	54,463,000
(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities	\$ 18,413,000	\$	22,436,000	\$	40,849,000	\$	11,508,000	\$ 12,474,000	\$	23,982,000	\$	6,905,000	\$	9,962,000	\$	16,867,000
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))	\$ 68.347.000	s	28.432.000	\$	96.779.000	s	56.433.000	\$ 20.701.000	s	77.134.000	\$	11.914.000	s	7.731.000	\$	19.645.000

3. Other Admissibility Criteria

a. Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount. 1118.230% 1041.892%

b. Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above.

\$ 2,594,436,255 \$ 2,227,629,796

- 4. Impact of Tax Planning Strategies
 - a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage.

	20	23	20	22	Change			
	(1)	(2)	(3)	(4)	(5) (Col. 1 - 3)	(6) (Col. 2 - 4)		
	Ordinary	Capital	Ordinary	Capital	Ordinary	Capital		
(a) Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage. 1. Adjusted Gross DTAs amount from Note 9A1 (c) 2. Percentage of adjusted gross DTAs by tax	\$ 80,036,000	\$ 28,432,000	\$ 67,541,000	\$ 20,701,000	\$ 12,495,000	\$ 7,731,000		
character attributable to the impact of tax planning strategies	0.000%	0.000%	0.000%	0.000%	0.000%	0.000%		
Net Admitted Adjusted Gross DTAs amount from Note 9A1(e)	\$ 68,347,000	\$ 28,432,000	\$ 56,433,000	\$ 20,701,000	\$ 11,914,000	\$ 7,731,000		
Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies	0.000%	0.000%	0.000%	0.000%	0.000%	0.000%		

b. Does the Company's tax-planning strategies include the use of reinsurance?

Yes [] No [X]

B. Deferred Tax Liabilities Are Not Recognized For the Following Amounts:

None

C. Current and Deferred Income Taxes

ent a	and Deferred Income Taxes						
			(1)		(2)		(3) (Col. 1 - 2)
1.	Current Income Tax		2023		2022		Change
	(a) Federal	\$	66,836,000	\$	23,410,000	\$	43,426,000
	(b) Foreign	\$	-	\$		\$	-
	(c) Subtotal (1a+1b)	\$	66,836,000	\$	23,410,000	\$	43,426,000
	(d) Federal income tax on net capital gains	\$	128,000	\$	(4,127,000)	\$	4,255,000
	(e) Utilization of capital loss carry-forwards	\$,	\$	-	\$	-
	(f) Other	\$	_	\$	_	\$	_
	(g) Federal and foreign income taxes incurred (1c+1d+1e+1f)	\$	66,964,000	\$	19,283,000	\$	47,681,000
2.	Deferred Tax Assets:						
	(a) Ordinary:						
	(1) Discounting of unpaid losses	\$	2,073,000	\$	1,147,000	\$	926,000
	(2) Unearned premium reserve	\$	-	\$	-	\$	-
	(3) Policyholder reserves	\$	-	\$	-	\$	-
	(4) Investments	\$	-	\$	-	\$	-
	(5) Deferred acquisition costs	\$	-	\$	-	\$	-
	(6) Policyholder dividends accrual	\$	-	\$	-	\$	-
	(7) Fixed assets	\$	2,572,000	\$	1,757,000	\$	815,000
	(8) Compensation and benefits accrual	\$	17,213,000	\$	14,101,000	\$	3,112,000
	(9) Pension accrual	\$	-	\$	-	\$	-
	(10) Receivables - nonadmitted	\$	17,290,000	\$	19,060,000	\$	(1,770,000)
	(11) Net operating loss carry-forward	\$	-	\$	-	\$	-
	(12) Tax credit carry-forward	\$	-	\$	-	\$	-
	(13) Other	\$	40,888,000	\$	31,476,000	\$	9,412,000
	(99) Subtotal (sum of 2a1 through 2a13)	\$	80,036,000	\$	67,541,000	\$	12,495,000
	(b) Statutory valuation allowance adjustment	\$	-	\$	-	\$	-
	(c) Nonadmitted	\$	11,689,000	\$	11,108,000	\$	581,000
	(d) Admitted ordinary deferred tax assets (2a99 - 2b - 2c)	\$	68,347,000	\$	56,433,000	\$	11,914,000
	(e) Capital:						
	(1) Investments	\$	22,478,000	\$	13,285,000	\$	9,193,000
	(2) Net capital loss carry-forward	\$	-	\$	-	\$	-
	(3) Real estate	\$	5,954,000	\$	7,416,000	\$	(1,462,000)
	(4) Other	\$	-	\$	-	\$	-
	(99) Subtotal (2e1+2e2+2e3+2e4)	\$	28,432,000	\$	20,701,000	\$	7,731,000
	(f) Statutory valuation allowance adjustment	\$	-	\$	-	\$	-
	(g) Nonadmitted	\$	-	\$	-	\$	-
	(h) Admitted capital deferred tax assets (2e99 - 2f - 2g)	\$	28,432,000	\$	20,701,000	\$	7,731,000
	(i) Admitted deferred tax assets (2d + 2h)	\$	96,779,000	\$	77,134,000	\$	19,645,000
3.	Deferred Tax Liabilities:						
	(a) Ordinary:						
	(1) Investments	\$	444,000	\$	366,000	\$	78,000
	(2) Fixed assets	\$	-	\$	-	\$	-
	(3) Deferred and uncollected premium	\$	-	\$	-	\$	-
	(4) Policyholder reserves	\$	-	\$	-	\$	-
	(5) Other	\$.	\$	-	\$	
	(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	\$	444,000	\$	366,000	\$	78,000
	(b) Capital:	1.		ر ا		١.	
	(1) Investments	\$	40,405,000	\$	23,616,000	\$	16,789,000
	(2) Real estate	\$	-	\$	-	\$	-
	(3) Other	\$	-	\$	-	\$	-
	(99) Subtotal (3b1+3b2+3b3)	\$	40,405,000	\$	23,616,000	\$	16,789,000
	(c) Deferred tax liabilities (3a99 + 3b99)	\$	40,849,000	\$	23,982,000	\$	16,867,000
4.	Net Deferred Tax Assets/Liabilities (2i - 3c)	\$	55,930,000	\$	53,152,000	\$	2,778,000

The change in net deferred income taxes is comprised of the following (this analysis is exclusive of nonadmitted assets as the change in nonadmitted assets is reported separately from the change in net deferred income taxes in unassigned surplus):

		2023			2022		Change				
	(1)	(2)	(3) (Col. 1 + 2)	(4)	(5)	(6) (Col. 4 + 5)	(7) (Col. 1 - 4)	(8) (Col. 2 - 5)	(9) (Col. 7 + 8)		
	Ordinary	Capital	Total	Ordinary	Capital	Total	Ordinary	Capital	Total		
Total deferred tax assets	\$ 80,036,000	\$ 28,432,000	\$ 108,468,000	\$ 67,541,000	\$ 20,701,000	\$ 88,242,000	\$ 12,495,000	\$ 7,731,000	\$ 20,226,000		
Total deferred tax liabilities	\$ (444,000)	\$ (40,405,000)	\$ (40,849,000)	\$ (366,000)	\$ (23,616,000)	\$ (23,982,000)	\$ (78,000)	\$ (16,789,000)	\$ (16,867,000)		
Net deferred tax asset (liability)	\$ 79,592,000	\$ (11,973,000)	\$ 67,619,000	\$ 67,175,000	\$ (2,915,000)	\$ 64,260,000	\$ 12,417,000	\$ (9,058,000)	\$ 3,359,000		
Tax effect of unrealized gains									\$ 16,789,000		
Tax effect of SSAP 92/SSAP 102									\$ 4,686,000		
Change in net deferred income tax									\$ 24,834,000		

D. Reconciliation of Federal Income Tax Rate to Actual Effective Rate

Among the more significant book to tax adjustments were the following:

	ı	
		12/31/2023
Provision computed at statutory rate	\$	59,534,000
Change in nonadmitted assets	\$	(255,000)
Tax exempt interest deduction	\$	(230,000)
100% dividend received from affiliate	\$	(18,688,000)
Dividends received deduction, net	\$	(577,000)
Nondeductible lobbying expenses	\$	71,000
§162(m)(6) limitation	\$	2,167,000
Other permanent differences	\$	486,000
Credits generated in current year	\$	(1,303,000)
Adjustment of prior year's tax	\$	925,000
Total	\$	42,130,000
Federal and foreign income taxes incurred	\$	66,836,000
Realized capital gains (losses) tax	\$	128,000
Change in net deferred income taxes	\$	(24,834,000)
Total statutory income taxes	\$	42,130,000

- E. Operating Loss and Tax Credit Carryforwards and Protective Tax Deposits
 - 1. At December 31, 2023, the Company did not have any unused operating loss carryforwards available to offset against future taxable income.
 - 2. The following are income taxes in the current and prior years that will be available for recoupment in the event of future net losses:

Year		Amounts
2023	\$	59,905,000
2022	\$	31,621,000
2021	\$	8,541,000
Total	\$	100,067,000

- 3. The Company did not have any protective tax deposits under Section 6603 of the Internal Revenue Code.
- F. Consolidated Federal Income Tax Return
 - 1 The Company's federal income tax return is consolidated with the following entities:

Wellmark of South Dakota, Inc.
Wellmark Health Plan of Iowa, Inc
Wellmark Synergy Health, Inc.
Wellmark Value Health Plan, Inc.
First Administrators, Inc.
Midwest Benefit Consultants, Inc.
Wellmark Holdings, Inc.

2 The manner in which the Board of Directors sets forth for allocating the consolidated federal income tax:

The method of allocation between the companies is subject to a written agreement, approved by the Board of Directors and the lowa Insurance Division. Allocation is based upon separate return calculations with current credit for net losses.

At December 31, 2023, the Company's tax related balance due from subsidiaries was \$27,611,260.

G. Federal and Foreign Income Tax Loss Contingencies

At December 31, 2023, it is not reasonably possible to determine the Company's amount of tax loss contingencies that will significantly increase or decrease within twelve months of the reporting date.

H. Repatriation Transition Tax (RTT)

Not applicable

I. Alternative Minimum Tax (AMT) Credit

The Inflation Reduction Act was enacted on August 16, 2022, and included a new corporate alternative minimum tax (CAMT). The CAMT is effective for tax years beginning after December 31, 2022. The Company is not an "applicable corporation" for purposes of the CAMT and therefore does not expect to be liable for CAMT in 2023.

NOTE 10 Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship Involved

The Company and Wellmark Health Plan of lowa, Inc. (WHPI), a wholly owned subsidiary, have a management agreement whereby WHPI agrees to pay the Company for costs related to services outlined in the agreement. These costs are computed on a monthly basis. For 2023 and 2022, these costs were \$133,481,763 and \$115,907,857, respectively. The Company and WHPI also have an intercompany tax sharing arrangement (See Note 9). For 2023 and 2022, the tax related balance due from WHPI under this tax sharing arrangement was \$23,728,990 and \$23,539,592, respectively.

The Company and Wellmark of South Dakota, Inc. (WSD), a wholly owned subsidiary, have an intercorporate service agreement whereby WSD agrees to pay the Company for costs related to services outlined in the agreement. These costs are computed on a monthly basis. For 2023 and 2022, these costs were \$82,552,782 and \$87,672,199, respectively. The Company and WSD also have an intercompany tax sharing arrangement (See Note 9). For 2023 and 2022, the tax related balance due from WSD under this tax sharing arrangement was \$3,684,952 and \$3,212,247, respectively.

The Company received dividends of \$89,500,000 and \$43,500,000 from WHPI in 2023 and 2022, respectively. The dividends reduced the inter-company payable to WHPI and were recorded in net investment income.

The Company received a cash dividend of \$1,200,000 from WSH in 2022. The dividend was recorded in net investment income.

In February 2021, the Company entered into a joint venture agreement to establish a newly formed entity, Wellmark Advantage Holdings, LLC. The Company holds a 49% ownership interest in this joint venture. Wellmark Advantage Holdings, LLC owns 100% of the capital stock of Wellmark Advantage Health Plan, Inc. (WAHP). WAHP is an insurance entity domiciled in Iowa and licensed to sell products in Iowa and South Dakota. The Company contributed capital totaling \$40,180,000 and \$9,794,610 to WAHP in 2023 and 2022, respectively.

B. Description of Transactions

See Note 10 A

C. Transactions with Related Parties Who Are Not Reported on Schedule Y

None

D. Amounts Due From or To Related Parties

At December 31, 2023, the Company reported \$114,722,610 as amounts due to subsidiaries and affiliates and \$12,310,568 as admitted amounts due from subsidiaries and affiliates. At December 31, 2022, the Company reported \$125,299,310 as amounts due to subsidiaries and affiliates and \$41,644,649 as admitted amounts due from subsidiaries and affiliates. The terms of the agreements require these amounts to be settled within 30 days.

E. Material Management or Service Contracts and Cost-Sharing Arrangements

The Company has an intercorporate services and investment and management agreement with some of its subsidiaries and affiliates to provide certain management and administrative services.

F. Guarantees or Undertakings

See Note 14

G. Nature of the Control Relationship

Not applicable

H. Amount Deducted from the Value of Upstream Intermediate Entity or Ultimate Parent Owned

Not applicable

I. Investments in SCA that Exceed 10% of Admitted Assets

The Company had no investments in SCA entities that exceeded 10% of the Company's admitted assets in 2023 or 2022.

J. Investments in Impaired SCAs

Not applicable

K. Investment in Foreign Insurance Subsidiary

Not applicable

L. Investment in Downstream Noninsurance Holding Company

The Company utilizes the look-through approach in valuing its investment in Wellmark Advantage Holdings, LLC (WAH) at \$15,359,341 and \$4,828,746 as of December 31, 2023 and 2022, respectively. WAH's financial statements are not audited and the Company has limited the value of its investment in WAH to the audited statutory equity of Wellmark Advantage Health Plan, Inc., a wholly owned insurance subsidiary of WAH. The Company considers all liabilities, commitments, contingencies, guarantees, or obligations of WAH in the determination of the carrying value of its investment in WAH.

M. All SCA Investments

(1) Balance Sheet Value (Admitted and Nonadmitted) All SCAs (Except 8bi Entities)

SCA Entity	Percentage of SCA Ownership	Gross Amount	Admitted Amount	١	lonadmitted Amount
a. SSAP No. 97 8a Entities					
Total SSAP No. 97 8a Entities	XXX	\$ -	\$ -	\$	-
b. SSAP No. 97 8b(ii) Entities					
Total SSAP No. 97 8b(ii) Entities	XXX	\$ 	\$ -	\$	-
c. SSAP No. 97 8b(iii) Entities					
Wellmark Holdings, Inc.	100.0%	\$ -	\$ -	\$	-
First Administrators, Inc.	100.0%	\$ 3,547,237	\$ -	\$	3,547,237
Midwest Benefit Consultants, Inc.	100.0%	\$ 5,884,563	\$ -	\$	5,884,563
Total SSAP No. 97 8b(iii) Entities	XXX	\$ 9,431,800	\$ -	\$	9,431,800
d. SSAP No. 97 8b(iv) Entities					
Total SSAP No. 97 8b(iv) Entities	XXX	\$ -	\$ -	\$	-
e. Total SSAP No. 97 8b Entities (except 8bi entities) (b+c+d)	XXX	\$ 9,431,800	\$ -	\$	9,431,800
f. Aggregate Total (a+ e)	XXX	\$ 9,431,800	\$ -	\$	9,431,800

(2) NAIC Filing Response Information

SCA Entity (Should be same entities as shown in M(1) above.)	Type of NAIC Filing	Date of Filing to the NAIC	NAIC Valuation Amount	NAIC Response Received Yes/No	NAIC Disallowed Entities Valuation Method, Resub- mission Required Yes/No	Code **
a. SSAP No. 97 8a Entities						
Total SSAP No. 97 8a Entities	XXX	XXX	\$ -	XXX	XXX	XXX
b. SSAP No. 97 8b(ii) Entities Total SSAP No. 97 8b(ii) Entities	XXX	XXX	\$ -	XXX	XXX	XXX
c. SSAP No. 97 8b(iii) Entities						
Wellmark Holdings, Inc.	S1	10/25/2016	\$ -	Yes	No	
First Administrators, Inc.	S1	10/25/2016	\$ -	Yes	No	
Midwest Benefit Consultants, Inc.	S1	10/25/2016	\$ -	Yes	No	
Total SSAP No. 97 8b(iii) Entities	XXX	XXX	\$ -	XXX	XXX	XXX
		-	-			
d. SSAP No. 97 8b(iv) Entities						
Total SSAP No. 97 8b(iv) Entities	XXX	XXX	\$ -	XXX	XXX	XXX
e. Total SSAP No. 97 8b Entities (except 8bi entities) (b+c+d)	XXX	XXX	\$ -	XXX	XXX	XXX
f. Aggregate Total (a+e)	XXX	XXX	\$ -	XXX	XXX	XXX

^{*} S1 - Sub-1, S2 - Sub-2 or RDF - Resubmission of Disallowed Filing

The Company is exempt from a Sub-2 filing for its SSAP 97 8b(iii) subsidiaries because they are fully nonadmitted.

N. Investment in Insurance SCAs

Not applicable

O. SCA or SSAP 48 Entity Loss Tracking

1	2	3	4	5	6
				Guaranteed	
				Obligation /	
				Commit-	
	Reporting		Reporting	ment	Amount of the
	Entity's	Accumulated	Entity's	for	Recognized
	Share of	Share of	Share of	Financial	Guarantee
	Net Income	Net Income	Equity, Including	Support	Under
Entity	(Loss)	(Losses)	Negative Equity	(Yes/No)	SSAP No. 5R
Wellmark Holdings, Inc.	\$ (445,356)	\$ (2,159,377)	\$ (2,102,344)	No	\$ -

The losses in Wellmark Holdings, Inc. have not impacted other investments.

NOTE 11 Debt

A. Debt Including Capital Notes

Not applicable

- B. FHLB (Federal Home Loan Bank) Agreements
 - (1) Nature of the Agreement

The Company became a member of the Federal Home Loan Bank (FHLB) of Des Moines during 2020. The Company has determined the estimated current maximum borrowing capacity as approximately \$68,000,000. The Company calculated this amount in accordance with FHLB Des Moines credit and collateral guidelines. When borrowings occur, it is anticipated that the Company's strategy will be to utilize these funds to meet daily liquidity needs. As of year-end, the Company has no outstanding advances with FHLB Des Moines.

(2) FHLB Capital Stock

a. Aggregate Totals

a. Aggregate rotals	
	Total
1. Current Year	
(a) Membership Stock - Class A	\$ -
(b) Membership Stock - Class B	\$ 2,148,700
(c) Activity Stock	\$ -
(d) Excess Stock	\$ -
(e) Aggregate Total (a+b+c+d)	\$ 2,148,700
(f) Actual or estimated Borrowing Capacity as Determined by the	
Insurer	\$ 68,000,000
2. Prior Year-end	
(a) Membership Stock - Class A	\$ -
(b) Membership Stock - Class B	\$ 4,227,700
(c) Activity Stock	\$ -
(d) Excess Stock	\$ -
(e) Aggregate Total (a+b+c+d)	\$ 4,227,700
(f) Actual or estimated Borrowing Capacity as Determined by the	
Insurer	\$ 115,000,000

¹¹B(2)a1(f) should be equal to or greater than 11B(4)a1(d)

^{**} I - Immaterial or M - Material

¹¹B(2)a2(f) should be equal to or greater than 11B(4)a2(d)

b. Membership Stock (Class A and B) Eligible and Not Eligible for Redemption

		1	2		Eligible for Redemption									
	Current Year Total (2+3+4+5+6)				3	6 1	4 Months to		5		6			
			Not Eligible for Redemption		Less Than 6 Months		Less Than 1 Year		ess Than Years	3 to 5 Years				
Membership Stock				'				,			<u>.</u>			
1. Class A	\$	-	\$ -	\$	-	\$	-	\$	-	\$	-			
2. Class B	\$	2,148,700	\$ 2,148,700	\$	-	\$	-	\$	-	\$	-			

11B(2)b1 Current Year Total (Column 1) should equal 11B(2)a1(a) Total (Column 1)

11B(2)b2 Current Year Total (Column 1) should equal 11B(2)a1(b) Total (Column 1)

(3) Collateral Pledged to FHLB

No amounts were pledged during the reporting period and no amounts were pledged as of December 31, 2023.

(4) Borrowing from FHLB

No amounts were borrowed during the reporting period and no amounts were outstanding as of December 31, 2023.

NOTE 12 Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

The Company sponsors a pension program (the program) covering substantially all employees. The pension program contains both a defined benefit and cash balance plan available to eligible employees depending on the date of hire. The defined benefit pension plan benefits are based on years of service and the employee's highest five consecutive years' compensation in the last ten years of service. Under the cash balance plan, employees earn annual credits based on a percentage of salary that are accumulated in an account that earns interest annually. Effective January 1, 2022, the program was amended to close participation to new entrants after December 31, 2021 and to provide for the cessation of all benefit accruals under all plan formulas under the program effective December 31, 2029.

The administration and recordkeeping services for the program are performed by Principal Life Insurance Company (collectively with Principal Financial Group as Principal). Pension plan assets are held in the Non-Contributory Retirement Program for Certain Employees of Wellmark, Inc. Trust (Trust) with Principal Trust Company as the trustee of the program.

The funding policy of the program is to contribute amounts sufficient to meet the minimum funding requirements set forth in the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 1996, plus additional amounts as determined to be appropriate from time to time. No voluntary contributions were made to the pension plan in 2023 or 2022. There are no current plans for the Company to make voluntary contributions to the pension plan in 2024.

The Company also sponsors a postretirement health care benefit plan. The plan has two separate benefit calculations available to employees depending on the date of hire. One plan contributes toward the cost of health care premiums based on years of service and is available to employees who retire from the Company who have at least ten years of service and have attained age 65 while in service to the Company. This plan also includes a life insurance benefit based on the employee's annual salary at retirement and is available to employees who retire from the Company who have at least five years of service and have attained age 55 while in service to the Company. The second plan option allows employees to accumulate annual credits in an account that earns interest annually and can be used to pay for health care premiums when the employee becomes Medicare eligible. Effective January 1, 2022, the postretirement health care benefit plan was amended to close the plan to additional participants and to freeze accruals of annual credits under the plan for all participants under age 62. The Company has not funded either the postretirement health care or life insurance plans but intends to meet the obligations of the plans through general assets of the Company.

A summary of assets, obligations and assumptions of the Pension and Other Postretirement Benefit Plans are as follows at December 31, 2023 and 2022:

(1) Change in Benefit Obligation

	Overfunded					Underfunded					
		2023		2022		2023		2022			
a. Pension Benefits											
Benefit obligation at beginning of year	\$	274,754,991	\$	337,274,566	\$	-	\$	-			
2. Service cost	\$	8,728,306	\$	10,935,546	\$	-	\$	-			
3. Interest cost	\$	14,003,395	\$	9,668,372	\$	-	\$	-			
Contribution by plan participants	\$	-	\$	-	\$	-	\$	-			
5. Actuarial gain (loss)	\$	(7,436,656)	\$	(57,043,864)	\$	-	\$	-			
Foreign currency exchange rate changes	\$	-	\$	-	\$	-	\$	-			
7. Benefits paid	\$	(18,647,087)	\$	(3,208,184)	\$	-	\$	-			
8. Plan amendments	\$	-	\$	-	\$	-	\$	-			
9. Business combinations, divestitures, curtailments, settlements											
and special termination benefits	\$	-	\$	(22,871,445)	\$	-	\$	-			
10. Benefit obligation at end of year	\$	271,402,949	\$	274,754,991	\$	-	\$	-			
		Overf	unde	ed		Underfunded					
		2023		2022		2023		2022			
b. Postretirement Benefits						<u>.</u>					
Benefit obligation at beginning of year	\$	_	\$	-	\$	27,718,747	\$	38,931,902			
2. Service cost	\$	-	\$	-	\$	42,051	\$	1,746,000			
3. Interest cost	\$	_	\$	-	\$	1,392,235	\$	1,063,000			
Contribution by plan participants	\$	_	\$	-	\$	-	\$	-			
5. Actuarial gain (loss)	\$	_	\$	-	\$	(123,366)	\$	(12,674,305)			
Foreign currency exchange rate changes	\$	_	\$	-	\$	-	\$	-			
7. Benefits paid	\$	-	\$	-	\$	(1,396,014)	\$	(1,347,850)			
8. Plan amendments	\$	_	\$	-	\$	-	\$	-			
9. Business combinations, divestitures, curtailments, settlements											
and special termination benefits	\$	-	\$	-	\$	-	\$	-			
10. Benefit obligation at end of year	\$	-	\$	-	\$	27,633,653	\$	27,718,747			

						Over	funded	d			Unde	funde	ed
					2023			202	2		2023		2022
c. Special or Contractual Benefits Per SS1. Benefit obligation at beginning of ye				\$		_	\$		_	\$	12,333,481	\$	13,583,888
Service cost	aı			φ \$		-	э \$		-	φ \$	25,747,843	\$ \$	22,909,672
3. Interest cost				\$		-	\$		-	\$	-	\$	-
4. Contribution by plan participants				\$		-	\$		-	\$	-	\$	-
5. Actuarial gain (loss)				\$ \$		-	\$ \$		-	\$	-	\$	-
 Foreign currency exchange rate cha Benefits paid 	inges			φ \$		-	э \$		-	\$ \$	(25,399,418)	\$ \$	(24,160,079)
8. Plan amendments				\$		_	\$		-	\$	(20,000,110)	\$	-
 Business combinations, divestitures and special termination benefits Benefit obligation at end of year 	, curtailments, settle	men	ts	\$ \$		-	\$ \$		-	\$ \$	- 12,681,906	\$ \$	- 12,333,481
Ç				φ		-	Ψ		-	Ψ	12,001,900	φ	12,333,401
(2) Change in Plan Assets	_												
		sion efits						etiremer enefits	nt		Special or Co Per S		tual Benefits No. 11
	2023		2022	2		2023			2022		2023		2022
a. Fair value of plan assets at beginning of year	\$ 287,220,882	\$	376,443	894	\$		_	\$		_	\$ -	9	-
b. Actual return on plan assets	\$ 27,592,911		(63,143				_	\$		_	\$ -		-
c. Foreign currency exchange rate	. , ,		(,	,,	,						·		
changes	\$ -	\$		-	\$		-	\$		-	\$ -		-
d. Reporting entity contribution e. Plan participants' contributions	\$ - \$ -	\$ \$		-	\$ \$		-	\$ \$		-	\$ - \$ -		- 5 -
f. Benefits paid	\$ (18,647,087)	\$	(3,208	- 3.184)			_	\$		-	\$ -		-
g. Business combinations, divestitures											·		
and settlements h. Fair value of plan assets at end of	\$ -	\$	(22,871	,445)) \$		-	\$		-	\$ -	,	-
year	\$ 296,166,706	\$	287,220	,882	\$		-	\$		-	\$ -	9	-
(3) Funded Status													
						Pensior	n Bene		•		Postretirem	ent B	
a. Components:					2023			202	2		2023		2022
Prepaid benefit costs				\$	78,204	.976	\$	89.40	0,430	\$	_	\$	_
Overfunded plan assets					(53,44	,	\$		34,539)	\$	-	\$	-
Accrued benefit costs				\$		-	\$		-	\$	40,328,793	\$	41,590,242
Liability for pension benefits				\$		-	\$		-	\$	(12,695,140)	\$	(13,871,495)
b. Assets and liabilities recognized:													
Assets (nonadmitted)				\$	24,763	3,757	\$	12,46	5,891	\$	-	\$	-
2. Liabilities recognized				\$		-	\$		-	\$	27,633,653	\$	27,718,747
c. Unrecognized liabilities				\$		-	\$		-	\$	-	\$	-
(4) Components of Net Periodic Benefit Cost													
(4) Components of Net 1 chodic Benefit Cost		Pension						etiremer	nt		Special or C	ontrac	tual Benefits
		efits		Benefits							Per S		
	2023	_	2022	<u>'</u>		2023			2022	_	2023		2022
0													
a. Service cost b. Interest cost	\$ 8,728,306 \$ 14,003,395	\$ \$	10,935 9,668	,	\$ \$	42 1,392	,051	\$ \$	1,746,00 1,063,00		\$ 25,747,843 \$ -		\$ 22,909,672 \$ -
c. Expected return on plan assets	\$ (16,709,257)	\$	(21,686			1,002	,200	\$	1,000,00	-	\$ -		-
d. Transition asset or obligation	\$ -	\$	•	-	\$		-	\$		-	\$ -		-
e. Gains and losses f. Prior service cost or credit	\$ 5,173,010 \$ -	\$ \$	2,680	,214	\$ \$	(1,299	,721)	\$ \$	05.07	-	\$ - \$ -		- 5 -
g. Gain or loss recognized due to a	5 -	Ф		-	Þ		-	ф	65,27	3	5 -	•	-
settlement or curtailment	\$ -	\$	6,400		\$		-	\$		-	\$ -		-
h. Total net periodic benefit cost	\$ 11,195,454	\$	7,997	,328	\$	134	,565	\$	2,874,27	3	\$ 25,747,843	(\$ 22,909,672
(5) Amounts in Unassigned Funds (Surplus)	Recognized as Con	npon	ents of	Net F	Periodic	Benefit	Cost						
						Pensior	Bene				Postretirem	ent B	
- 14		-4			2023			202	2	_	2023	_	2022
 a. Items not yet recognized as a compon year 	ent of net periodic co	St -	prior	\$	76,934	539	\$	58 22	8,430	\$	(13,871,495)	\$	(1,131,917)
b. Net transition asset or obligation recog	nized			\$. 5,55	-	\$	JU,	-,	\$	-	\$	-
c. Net prior service cost or credit arising of	• .			\$		-	\$		-	\$	-	\$	<u>-</u>
 d. Net prior service cost or credit recognize. e. Net gain and loss arising during the pe 				\$ \$	(18,320	-) 310\	\$ \$	27 70	- 6,423	\$ \$	(123,366)	\$ \$	(65,273) (12,674,305)
f. Net gain and loss ansing during the pe				\$ \$	(5,173		\$ \$		80,423 80,314)	\$ \$	1,299,721	\$ \$	(12,017,000)
g. Items not yet recognized as a compon current year	ent of net periodic co	st -		\$	53,441		\$	•	4,539	\$	(12,695,140)	\$	(13,871,495)
				·						•		φ	(10,071,730)
(6) Amounts in Unassigned Funds (Surplus)	That Have Not Yet	Bee	n Recog	gnized	d as Co	mponer	nts of	Net Per	riodic Ber	nefit (Cost		
					2023	Pensior	Bene	efits 202	2		Postretirem 2023	ent B	enefits 2022
a. Net transition asset or obligation				\$	2023		\$	202	<u>-</u>	\$		\$	-
b. Net prior service cost or credit				\$		-	\$		-	\$	-	\$	- -
c. Net recognized gains and losses				\$	53,441	,219	\$	76,93	4,539	\$	(12,695,140)	\$	(13,871,495)

(7) Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost as of December 31:

() Weighted-Average Assumptions used to Determine Net Periodic Benefit Cost as of Decer	Tibel 31.	
	Pension B	enefits
	2023	2022
a. Weighted average discount rate	5.30%	3.00%
b. Expected long-term rate of return on plan assets	6.50%	6.00%
c. Rate of compensation increase	3.00 - 8.00%	3.50 - 8.00%
d. Interest crediting rates (for cash balance plans and other plans with promised interest c	rediting rates) 3.50%	2.00 - 3.00%
Weighted-Average Assumptions Used to Determine Projected Benefit Obligations as of De	cember 31:	
	Pension B	enefits
	2023	2022
e. Weighted average discount rate	5.00%	5.30%
f. Rate of compensation increase	3.00 - 8.00%	3.00 - 8.00%
g. Interest crediting rates (for cash balance plans and other plans with promised interest c	rediting rates) 4.00%	3.50%
Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs as of Dece	ember 31:	
	Postretiremen	nt Benefits
	2023	2022
a. Weighted average discount rate	5.20%	2.80%
b. Expected long-term rate of return on plan assets	N/A	N/A
c. Rate of compensation increase	3.00 - 8.00%	3.50 - 8.00%
d. Interest crediting rates (for cash balance plans and other plans with promised interest c	rediting rates) N/A	N/A
Weighted-Average Assumptions Used to Determine Projected Benefit Obligations as of De	cember 31:	
	Postretiremen	nt Benefits
	2023	2022
e. Weighted average discount rate	5.00%	5.20%
f. Rate of compensation increase	3.00 - 8.00%	3.00 - 8.00%
	11.1	

(8) Accumulated Benefit Obligation for Defined Benefit Pension Plans

The amount of the accumulated benefit obligation for the defined benefit pension plan was \$248,992,369 for the current year and \$253,151,073 for the prior year.

N/A

N/A

(9) Assumed Health Care Cost Trend Rate(s) For Postretirement Benefits Other than Pensions

g. Interest crediting rates (for cash balance plans and other plans with promised interest crediting rates)

For postretirement benefits other than pensions, for measurement purposes, 7.5% (pre-65) and 6.5% (post-65) annual rates of increase in the per capita cost of covered health care benefits were assumed for 2023. These rates grade down annually to 4.5% for 2033 and beyond.

(10) The following estimated future payments, which reflect expected future service, as appropriate, are expected to be paid in the years indicated:

Pension Benefits	 Amount
a. 2024	\$ 19,740,000
b. 2025	\$ 20,040,000
c. 2026	\$ 20,720,000
d. 2027	\$ 21,120,000
e. 2028	\$ 20,750,000
f. 2029 through 2033	\$ 109,120,000
Postretirement Benefits	Amount
a. 2024	\$ 2,630,000
b. 2025	\$ 2,230,000
c. 2026	\$ 2,130,000
d. 2027	\$ 2,210,000
e. 2028	\$ 2,280,000
f. 2029 through 2033	\$ 10,600,000

(11) Estimate of Contributions Expected to be Paid to the Plan

The Company does not have any regulatory contribution requirements for 2024. In addition, there are no current plans for the Company to make voluntary contributions to the defined benefit pension plan in 2024.

(12) Amounts and Types of Securities Included in Plan Assets

Not applicable

(13) Alternative Method Used to Amortize Prior Service Amounts or Net Gains and Losses

Not applicable

(14) Substantive Comment Used to Account for Benefit Obligation

Not applicable

(15) Cost of Providing Special or Contractual Termination Benefits Recognized

Not applicable

(16) Reasons for Significant Gains/Losses Related to Changes in Defined Benefit Obligation and any Other Significant Change in the Benefit Obligations or Plan Assets Not Otherwise Apparent

During the year ended December 31, 2023, the pension benefit obligation generated a loss due to a decrease in the discount rate, a gain due to a favorable asset return, an active participant experience loss due to higher than expected compensation during 2022, and an overall gain due to cash balance interest crediting rate and lump sum conversion assumption changes. During the year ended December 31, 2023, the other postretirement benefit obligation experienced a loss due to a decrease in the discount rate.

(17) Accumulated Postretirement and Pension Benefit Obligation and Fair Value of Plan Assets for Defined Postretirement and Pension Benefit Plans

The pension plan was in an overfunded status at December 31, 2023 and 2022. As required by SSAP 102, overfunded plan assets are nonadmitted. The Company has not funded either the postretirement health care or life insurance plans. The impact to surplus to recognize the unfunded status of the Other Postretirement Benefit Plans was (\$12,695,140) and (\$13,871,495) at December 31, 2023 and 2022, respectively.

(18) Full Transition Surplus Impact of SSAP 102

Not applicable

B. Investment Policies and Strategies

The Company's pension plan assets are invested in the Trust. The investment program for the Trust is based on the precepts of capital market theory that are generally accepted and followed by institutional investors, who by definition are long-term oriented investors. This philosophy holds that:

- 1. Increasing risk is rewarded with compensating returns over time and therefore, prudent risk taking is justifiable for long term investors.
- 2. Risk can be controlled through diversification of asset classes and investment approaches as well as diversification of individual securities.
- 3. Risk is reduced by time, and over time the relative performance of different asset classes is reasonably consistent. Over the long-term, equity investments have provided and should continue to provide superior returns over other security types. Fixed-income securities can dampen volatility and provide liquidity in periods of depressed economic activity. Lengthening duration of fixed income securities may reduce surplus volatility.
- 4. The strategic or long-term allocation of assets among various asset classes is an important driver of long term returns.
- 5. Relative performance of various asset classes is unpredictable in the short-term and attempts to shift tactically between asset classes are unlikely to be rewarded.

Investments will be made for the sole interest of the participants of the pension plan participating in the Trust. Accordingly, the assets of the Trust shall be invested in accordance with these objectives:

- 1. To seek and maintain an adequate funded status with regard to current liabilities within a targeted range.
- 2. To manage overall costs of running the pension plan at levels favorable to industry benchmarks.
- 3. To ensure assets are available to meet current and future benefit and expense obligations when due

C. Fair Value of Plan Assets

(1) Fair Value Measurements of Plan Assets at Reporting Date

Description For Each Class of Plan Assets		(Level 1)		(Level 2)	(Level 3)			Total
Cash Equivalents: Money Market Mutual Funds	\$	646,908	\$	-	\$	-	\$	646,908
Common/Collective Trusts: Equity Accounts	\$	-	\$	20,833,697	\$	-	\$	20,833,697
Pooled Separate Accounts: Fixed Income Account	\$	-	\$	172,144,653	\$	-	\$	172,144,653
Mutual Funds: Equity Funds	\$	12,430,508	\$	-	\$	-	\$	12,430,508
Mutual Funds: Fixed Funds	\$	9,489,288	\$	-	\$	-	\$	9,489,288
Total Plan Assets	\$	22,566,704	\$	192,978,350	\$	-	\$	215,545,054

Pension plan assets also include \$4,915,620 of hedge funds where fair value is measured at net asset value (NAV) per share as a practical expedient and \$75,706,032 of limited partnerships which are accounted for under the equity method.

(2) Valuation Technique(s) and Inputs Used to Measure Fair Value

Generally, Level 1 financial instruments consist of money market funds and mutual funds that are actively traded and have quoted prices available. Mutual funds are valued at NAV of shares held based on the latest quoted market price. Financial instruments included in Level 2 consist of common/collective trusts and pooled separate accounts that have direct or indirect price inputs that are observable in active markets or are measured at NAV. The fair value of the Company's hedge funds are estimated using NAV as a practical expedient. This practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported NAV. The Trust's limited partnership investments are initially recorded at cost. The carrying amounts are then increased or decreased to reflect the Trust's share of the income or loss. Quoted market prices do not exist for the limited partnerships. It is not practicable to estimate the fair value of the Trust's limited partnership investments due to the private and, in certain instances, confidential nature of the underlying investments in the partnerships, the specialized knowledge of specific industries and transactions required, and the time lag with which information is available from the limited partnerships. The underlying net assets within each limited partnership are measured at fair value; therefore, the equity method value is considered a reasonable proxy for fair value.

The Company obtains prices and/or relevant inputs to fair value calculations from external investment managers or from the custodian of the pension assets, which uses a third party pricing service. For securities not actively traded, the investment manager and/or pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment conditions, and nonbinding broker quotes. Additionally, for investments that do not have quoted market prices whereby fair value is measured using NAV per share as a practical expedient, inputs used in the valuation methodologies also include redemption frequency and redemption notice periods, to give consideration to liquidity constraints, if applicable.

D. Basis Used to Determine Expected Long-Term Rate-of-Return

The basis of the overall expected long-term rate of return on assets assumption is a forward-looking approach based on the current long-term capital market outlook assumptions of the asset categories the Trust invests in and the Trust's target asset allocation.

The assumed target asset allocation for the program is as follows: 58.5% fixed income, 20% private equity, 17% publicly-traded equity securities, 3% hedge funds, and 1.5% cash and cash equivalents. Portfolio expectations were estimated through a combination of underlying asset assumptions including geometric returns, distributions, and correlations. Using these assumptions, the Company selected the expected return on asset assumption of 6.50% for 2023. This rate is net of both investment and other administrative expenses charged to the Trust.

E. Defined Contribution Plan

The Company also sponsors a defined contribution plan (the plan) which is qualified under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees of the Company and subsidiaries. Employees can contribute a maximum of 80% of their annual salary to the plan (up to the elective deferral limits set by the Commissioner of Internal Revenue). The Company will contribute an amount equal to 100% of the first 4% of salary contributed by the employee. The plan also provides for additional employer contributions at the discretion of the Board of Directors.

Effective January 1, 2022, the plan was amended to provide different employer contributions to employees hired or rehired effective January 1, 2022 or after. For participants hired or rehired on or after January 1, 2022, the Company will contribute an amount equal to 100% of the first 6% of salary contributed by the employee. The Company will also make an annual contribution for these participants of 2%, 3% or 4% based on their age and years of service. To be eligible for the annual contribution, a participant is required to be an active employee on the last day of the plan year. Participants hired on or before December 31, 2021 will continue to receive a Company contribution in an amount equal to 100% of the first 4% of salary contributed by the employee.

Recordkeeping responsibilities for the plan are performed by Principal. The Company's contribution for this plan was \$4,507,372 and \$4,334,355 for 2023 and 2022, respectively

F. Multiemployer Plans

Not applicable

G. Consolidated/Holding Company Plans

The Company is the plan sponsor of a pension program and a postretirement health and life benefit program which cover substantially all employees of the consolidated group.

H. Postemployment Benefits and Compensated Absences

Not applicable

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

The Company plans to return any subsidy received to retirees in the form of higher postretirement welfare benefits. Therefore, the effects of the subsidy are not reflected in the measurement of the accumulated postretirement benefit obligation or the net periodic benefit cost.

NOTE 13 Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations

A. Number of Shares and Par or Stated Value of Each Class

Not applicable

B. Dividend Rate, Liquidation Value and Redemption Schedule of Preferred Stock Issues

Not applicable

C. Dividend Restrictions

Not applicable

D. Dates and Amounts of Dividends Paid

Not applicable

E. Profits that may be Paid as Ordinary Dividends to Stockholders

Not applicable

F. Restrictions Placed on Unassigned Funds (Surplus)

Not applicable

G. Amount of Advances to Surplus not Repaid

Not applicable

H. Amount of Stock Held for Special Purposes

Not applicable

I. Reasons for Changes in Balance of Special Surplus Funds from Prior Period

Not applicable

J. The Portion of Unassigned Funds (Surplus) Represented or Reduced by Cumulative Unrealized Gains and Losses is \$

\$ 793,429,223

K. The Reporting Entity Issued the Following Surplus Debentures or Similar Obligations

Not applicable

L. The Impact of any Restatement Due to Prior Quasi-Reorganizations

Not applicable

M. Effective Date of Quasi-Reorganization for a Period of Ten Years Following Reorganization

Not applicable

NOTE 14 Liabilities, Contingencies and Assessments

A. Contingent Commitments

(1) The Company is required by licensure requirements of the Blue Cross Blue Shield Association (BCBSA) to execute parental guarantees for its licensed controlled affiliates, pursuant to which the Company guarantees to the full extent of its assets all contractual and financial obligations of WHPI, WSD, FAI, WSH and WVHP to their respective customers. Through parental guarantees executed between the Company and WSH and WVHP, the Company guarantees that WSH and WVHP are in compliance with the lowa statutory minimum for HMO capital and surplus of \$1,000,000 or the statutory minimum for risk-based capital for health organizations, whichever is greater. Also, the Company, as the parent of WHPI is required by the lowa Insurance Division to guarantee the obligations of WHPI to pay for services to enrollees up to \$1,100,000.

The Company is also required by licensure requirements of the BCBSA to execute a parental guarantee for WAHP, pursuant to which the Company guarantees to the full extent of its assets all contractual and financial obligations to members proportionate to the Company's subsidiary holding company's ownership interest in WAHP.

(2) Detail of Other Contingent Commitments

Not applicable

(3) Guarantee Obligations

Not applicable

B. Assessments

(1) Assessments Where Amount is Known or Unknown

The Company is subject to health related assessments by the lowa Comprehensive Health Association and the lowa Individual Health Benefit Reinsurance Association for high risk insurance pools. The Company accrued a net admitted receivable of \$1,080,000 and a liability of \$9,190,000 for estimated health related assessments as of December 31, 2023.

(2) Assessments

Not applicable

(3) Guaranty Fund Liabilities and Assets Related to Assessments from Insolvencies for Long-Term Care Contracts

Not applicable

C. Gain Contingencies

Not applicable

D. Claims Related Extra Contractual Obligations and Bad Faith Losses Stemming From Lawsuits

Not applicable

E. Joint and Several Liabilities

Not applicable

F. All Other Contingencies

The Company, along with the BCBSA and Blue Cross and/or Blue Shield licensees, or Blue Plans across the country, is a defendant in a single multi-district consolidated lawsuit In re Blue Cross Blue Shield Antitrust Litigation that is pending in the United States District Court for the Northern District of Alabama. Generally, the litigation alleges that the BCBSA and Blue Plans have engaged in activities in violation of the Sherman Act and related state laws through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions and other arrangements. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers. The Company, the BCBSA and all other Blue Cross and/or Blue Shield licensees, have reached a settlement with the health plan subscriber class plaintiffs. This settlement has been preliminarily approved by the United States District Court for the Northern District of Alabama, though is still subject to ongoing appeals. The court currently is supervising the final class settlement approval process. There have been several additional individual lawsuits filed by groups and members who opted out of the subscriber class. The Company has made adequate provision for its proportional share of the settlement and any damages that may result from the opt-out suits. The provider class litigation is proceeding.

In the ordinary course of business, the Company is involved in and subject to claims, contractual disputes and other uncertainties, which the Company defends vigorously. While the ultimate outcome of any other claims cannot be presently determined, in the opinion of management, adequate provision has been made for any potential losses which may result from these actions and the Company expects any liability that could result will not materially affect its financial position.

NOTE 15 Leases

- A. Lessee Operating Lease
 - (1) Lessee's Leasing Arrangements
 - a. Rental Expense

The Company leases office space and equipment under various noncancelable operating lease agreements that expire through September 2033. Rental expense associated with these lease arrangements was approximately \$1,332,881 and \$1,180,638 for 2023 and 2022, respectively.

b. Basis on Which Contingent Rental Payments are Determined

Not applicable

c. Existence and Terms of Renewal or Purchase Options and Escalation Clauses

Certain rental commitments have renewal options extending through the year 2035. Some of these renewals are subject to adjustments in future periods.

d. Restrictions Imposed by Lease Agreements

Not applicable

e. Identification of Lease Agreements That Have Been Terminated Early

- (2) Leases with Initial or Remaining Noncancelable Lease Terms in Excess of One Year
 - a. At December 31, 2023, the minimum aggregate rental commitments are as follows:

	Operating Leases
1. 2024	\$ 949,843
2. 2025	\$ 875,998
3. 2026	\$ 436,541
4. 2027	\$ 398,331
5. 2028	\$ 344,837
6. Thereafter	\$ 1,294,726
7. Total (sum of 1 through 6)	\$ 4,300,276

b. Total of Minimum Rentals to be Received in the Future Under Noncancelable Subleases

Not applicable

(3) For Sale-Leaseback Transactions

Not applicable

B. Lessor Leases

Not applicable

NOTE 16 Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

Not applicable

NOTE 17 Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

Not applicable

NOTE 18 Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. ASO Plans

Not applicable

B. ASC Plans

The gain (loss) from operations from Administrative Services Contract (ASC) uninsured plans and the uninsured portion of partially insured plans was as follows during 2023:

Uninsured

	ASC Uninsured Plans	F	Portion of Partially Insured Plans	Total ASC
a. Gross reimbursement for medical cost incurred	\$ 1,768,990,293	\$	1,623,791,793	\$ 3,392,782,086
b. Gross administrative fees accrued c. Other income or expenses (including interest paid to or received from	\$ 50,763,817	\$	98,148,344	\$ 148,912,161
plans)	\$ -	\$	-	\$ -
d. Gross expenses incurred (claims and administrative) (a+b+c)	\$ 1,819,754,110	\$	1,721,940,137	\$ 3,541,694,247
e. Total net gain or loss from operations	\$ (6,819,497)	\$	(16,041,059)	\$ (22,860,556)

C. Medicare or Similarly Structured Cost Based Reimbursement Contract

Reimbursements from Centers for Medicare and Medicaid Services (CMS) for the Company's participation in the Medicare Part D program for the year ended December 31, 2023 were \$46,856,082. This amount represents pharmacy benefit cost reimbursements for the Reinsurance Subsidy and Low-Income Cost Sharing Subsidy elements of the Medicare Part D program.

At December 31, 2023, the Company has a receivable of \$2,411,107 from CMS for these reimbursements and has recorded a payable of \$12,127,956 for pre-funded amounts received from CMS not applied to benefit payments.

During the year, the Company returned a net amount of \$14,796,250 for prior year pre-funded amounts from CMS not applied to benefit payments.

NOTE 19 Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

NOTE 20 Fair Value Measurements

A. Fair Value Measurements

(1) Fair Value Measurements at Reporting Date

Description for Each Class of Asset or Liability	(Level 1)	(Level 2)	(Level 3)	١	Net Asset Value (NAV)	Total
a. Assets at fair value Cash Equivalents: Exempt Money Market Mutual Funds Cash Equivalents: Other Money Market	\$ 207,453,112	\$ -	\$ 1	\$	-	\$ 207,453,112
Mutual Funds	\$ 715,662	\$ -	\$ -	\$	-	\$ 715,662
Cash Equivalents: Sweep Account	\$ -	\$ 7,589,867	\$ -	\$	-	\$ 7,589,867
Bonds: Industrial & Miscellaneous	\$ -	\$ 54,315,317	\$ -	\$	-	\$ 54,315,317
Bonds: Bank Loans Preferred Stock: Industrial &	\$ -	\$ 3,434,086	\$ -	\$	-	\$ 3,434,086
Miscellaneous Common Stock: Industrial &	\$ 1,721,443	\$ -	\$ -	\$	-	\$ 1,721,443
Miscellaneous	\$ 562,641,809	\$ 2,148,700	\$ 2,787,112	\$	-	\$ 567,577,621
Common Stock: Mutual Funds Other Invested Assets: Residual	\$ 209,528,175	\$ -	\$ -	\$	-	\$ 209,528,175
Tranches	\$ _	\$ 769,010	\$ -	\$	_	\$ 769,010
Total Assets at Fair Value/NAV	\$ 982,060,201	\$ 68,256,980	\$ 2,787,112	\$	-	\$ 1,053,104,293

(2) Fair Value Measurements in Level 3 of the Fair Value Hierarchy

Description	nning Balance 01/01/2023	Transfers Into Level 3	Transfers Out of Level 3	Total Gains and (Losses) Included In Net Income	Total Gains and (Losses) Included In Surplus	Purchases	Issuances	Sales	Settlements	Ending Balance at 12/31/2023
a. Assets										
Common Stock - Industrial & Miscellaneous	\$ 2,702,704	\$ -	\$ -	\$ -	\$ 84,408	\$ -	\$ -	\$ -	\$ -	\$ 2,787,112
Total Assets	\$ 2,702,704	\$ -	\$ -	\$ -	\$ 84,408	\$ -	\$ -	\$ -	\$ -	\$ 2,787,112

(3) Policies When Transfers Between Levels Are Recognized

The Company recognizes transfers between fair value hierarchy levels at the end of the reporting period.

(4) Description of Valuation Techniques and Inputs Used in Fair Value Measurement

Bonds, structured securities, and surplus notes (other invested assets) are reported within Level 2 of the fair value hierarchy; all of these securities have direct or indirect price inputs that are observable in active markets. Fair values of these fixed income instruments are based on quoted market prices where available. The Company obtains at least one price from a third party pricing service or its custodian, which also uses a pricing service. In most instances, the Company obtains more than one price and evaluates between the pricing sources for any outliers or stale prices. Assuming prices are not stale and are reasonable between sources, the Company follows a pre-established hierarchy to conclude on which pricing source to utilize.

The pricing services normally derive security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the market for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment conditions, and nonbinding broker quotes.

Common stock reported within Level 2 of the fair value hierarchy is FHLB Class B Membership stock. This stock is non-redeemable and is reported at par, which is considered a proxy for fair value.

The Level 3 financial instrument is a privately held stock whose fair value is determined based on the unaudited GAAP equity per outstanding common share on a quarterly basis and on the audited GAAP equity per outstanding common share at calendar year end.

(5) Fair Value Disclosures for Derivative Assets and Liabilities

Not applicable

B. Fair Value Reporting under SSAP 100 and Other Accounting Pronouncements

Statutory guidance requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in the statements of assets, liabilities, capital and surplus. The carrying amounts for cash, receivable for securities, accrued investment income, premium receivables, other receivables, amounts due to/from affiliates, unearned premiums, accounts payable and accrued expenses, and certain other liabilities approximate fair value because of the short-term nature of these items.

C. Aggregate Fair Value For All Financial Instruments and the Level Within the Fair Value Hierarchy in Which the Fair Value Measurements in Their Entirety Fall

Type of Financial	Aggregate						Net A	sset Value		ot Practicable
Instrument	Fair Value	Α	dmitted Assets	(Level 1)	(Level 2)	(Level 3)	(NAV)	(Ci	arrying Value)
Cash Equivalents	\$ 215,758,641	\$	215,758,641	\$ 208,168,774	\$ 7,589,867	\$ -	\$		\$	-
Short-Term Investments	\$ 9,317,548	\$	9,313,497	\$ -	\$ 9,317,548	\$ -	\$	-	\$	-
Bonds	\$ 1,014,945,951	\$	1,046,468,772	\$ -	\$ 1,014,945,951	\$ -	\$	-	\$	-
Preferred Stock	\$ 1,721,443	\$	1,721,443	\$ 1,721,443	\$ -	\$ -	\$	-	\$	-
Common Stock	\$ 777,105,796	\$	777,105,796	\$ 772,169,984	\$ 2,148,700	\$ 2,787,112	\$	-	\$	-
Other Invested Assets	\$ 1,468,184	\$	1,389,169	\$ -	\$ 1,468,184	\$ _	\$	-	\$	_

D. Not Practicable to Estimate Fair Value

Not applicable

E. NAV Practical Expedient Investments

NOTE 21 Other Items

A. Unusual or Infrequent Items

Not applicable

B. Troubled Debt Restructuring

Not applicable

C. Other Disclosures

Assets in the amount of \$65,399,739 at December 31, 2023 were committed to purchase mortgage-backed securities in 2024.

D. Business Interruption Insurance Recoveries

Not applicable

E. State Transferable and Non-transferable Tax Credits

Not applicable

- F. Subprime Mortgage Related Risk Exposure
 - (1) Description of the Subprime-Mortgage-Related Risk Exposure and Related Risk Management Practices

The Company's investment policy, approved by the Board of Directors, requires the use of high quality fixed income investments to cover its contractual liabilities. The investment policy requires that the Company's fixed income portfolio, excluding non-agency mortgage-backed securities, have a minimum average quality rating of BBB+ and the total of below investment grade securities, excluding non-agency mortgage-backed securities, is limited to 10% of the total portfolio. Further, no single issue, with the exception of US Government and Agency securities, can exceed 5% of an external investment manager's portfolio at time of purchase. The Company allows certain external investment managers to purchase non-agency mortgage-backed securities, and credit quality of those securities is at manager discretion with NAIC designation 1 or 2 preferred. The Company utilizes its strategic and tactical asset allocation to manage risk exposure, through allocations to various external investment managers with varying mandates.

The Company's exposure to subprime mortgages at December 31, 2023 is 1.7% of its total portfolio. The Company is receiving principal and interest payments on the subprime mortgage securities, and the Company does not require sale of these types of assets to meet future cash flow requirements. These securities are in gross unrealized gain and loss positions of \$1,019,626 and \$4,296,334, respectively, as of December 31, 2023. While no single definition exists for subprime, these securities are considered higher risk and carry higher than prime rates of interest. In addition to the interest rates, the Company considers the FICO scores below 660, level of documentation, evidence of delinquency, foreclosure, judgments or bankruptcy and other factors that limit the borrower's ability to service the debt when determining if a security should be classified as subprime.

(2) Direct Exposure Through Investments in Subprime Mortgage Loans

Not applicable

(3) Direct Exposure Through Other Investments

	Actual Cost	ook/Adjusted arrying Value (excluding interest)	Fair Value	Other-Than- Temporary Impairment Losses Recognized
a. Residential mortgage backed securities	\$ 49,583,546	\$ 50,682,318	\$ 48,223,965	\$ 223,147
b. Commercial mortgage backed securities	\$ -	\$ -	\$ -	\$ -
c. Collateralized debt obligations	\$ -	\$ -	\$ -	\$ -
d. Structured securities	\$ 7,972,126	\$ 8,001,293	\$ 8,025,767	\$ -
e. Equity investment in SCAs *	\$ -	\$ -	\$ -	\$ -
f. Other assets	\$ -	\$ -	\$ -	\$ -
g. Total (a+b+c+d+e+f)	\$ 57.555.672	\$ 58.683.611	\$ 56.249.732	\$ 223.147

^{*} These investments comprise

(4) Underwriting Exposure to Subprime Mortgage Risk Through Mortgage Guaranty or Financial Guaranty Insurance Coverage

Not applicable

G. Retained Assets

Not applicable

H. Insurance-Linked Securities (ILS) Contracts

Not applicable

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable

NOTE 22 Events Subsequent

Type I – Recognized Subsequent Events:

Subsequent events have been considered through February 20, 2024 for the statutory statement issued on March 1, 2024.

Type II – Nonrecognized Subsequent Events:

Subsequent events have been considered through February 20, 2024 for the statutory statement issued on March 1, 2024.

WVHP has requested approval from the lowa Insurance Division to redeem 40,000 shares of outstanding stock from the Company at \$100 per share, for a total cash receipt of \$4,000,000. WVHP also requested approval from the lowa Insurance Division to pay an extraordinary dividend of \$1,000,000 to the Company. These transactions are anticipated to occur during the first quarter of 2024 and will not have a material impact on the Company's financial condition.

^{0.000%} of the companies invested assets.

NOTE 23 Reinsurance

Not applicable

NOTE 24 Retrospectively Rated Contracts & Contracts Subject to Redetermination

Method Used to Estimate Accrued Retrospective Premium Adjustments

The Company's participation in the Medicare Part D program includes a risk sharing provision with CMS. The Company estimates accrued retrospective premium adjustments for its Medicare Part D products through a prescribed formula approach. CMS adjusts its payments to the Company based on how actual benefit costs varied from the costs anticipated in the Company's bid for the Medicare Part D products. At December 31, 2023, the Company had five prior years remaining to be settled with CMS for the Medicare Part D products. The risk sharing amounts relating to all other prior years have been settled with CMS.

The Company estimates accrued retrospective premium adjustments for individuals, small groups and large groups according to retrospective rating features pursuant to the medical loss ratio rebate requirements subject to the Public Health Service Act.

Retrospective Premiums Recorded Through Written Premium or Adjustment to Earned Premium

The Company records accrued retrospective premium as an adjustment to earned premium.

Amount and Percentage of Net Premiums Written Subject to Retrospective Rating Features

The amount of net premiums written by the Company at December 31, 2023 that are subject to retrospective rating features was \$1,790,023,509, which represented 68.4% of the total net premiums written by the Company. No other net premiums written by the Company are subject to retrospective rating features.

Medical Loss Ratio Rebates Required Pursuant to the Public Health Service Act

The Company estimates no medical loss ratio rebates required pursuant to the Public Health Service Act at December 31, 2023.

Risk Sharing Provisions of the Affordable Care Act

Operations (Revenue & Expense)

(1) Did the reporting entity write accident and health insurance premium which is subject to the Affordable Care Act risk sharing provisions (YES/NO)?	Yes [X] No []
(2) Impact of Risk Sharing Provisions of the Affordable Care Act on admitted assets, liabilities and revenue for the current year:	Amount
a. Permanent ACA Risk Adjustment Program	
Assets	
1. Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments)	\$ 21,070,000
Liabilities	
2. Risk adjustment user fees payable for ACA Risk Adjustment	\$ 115,268
3. Premium adjustments payable due to ACA Risk Adjustment (including high risk pool premium)	\$ 1,715,000
Operations (Revenue & Expense) 4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk	

4. Reported as revenue in premium for accident and nearth contracts (written/collected) due to ACA Risk	
Adjustment	\$ 21,291,784
Reported in expenses as ACA risk adjustment user fees (incurred/paid)	\$ 115,532
b. Transitional ACA Reinsurance Program	
Assets	
Amounts recoverable for claims paid due to ACA Reinsurance	\$ -
Amounts recoverable for claims unpaid due to ACA Reinsurance (Contra Liability)	\$ -
Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	\$ -
Liabilities	
Liabilities for contributions payable due to ACA Reinsurance – not reported as ceded premium	\$ -
5. Ceded reinsurance premiums payable due to ACA Reinsurance	\$ -
Liabilities for amounts held under uninsured plans contributions for ACA Reinsurance	\$ -
Operations (Revenue & Expense)	
7. Ceded reinsurance premiums due to ACA Reinsurance	\$ -
8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$ -
9 ACA Reinsurance contributions – not reported as ceded premium	\$ _

Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$
ACA Reinsurance contributions – not reported as ceded premium	\$
c. Temporary ACA Risk Corridors Program	
Assets	
Accrued retrospective premium due to ACA Risk Corridors	\$
Liabilities	
Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	\$

3. Effect of ACA Risk Corridors on net premium income (paid/received)	\$ -
4. Effect of ACA Risk Corridors on change in reserves for rate credits	\$ -

(3) Roll forward of prior year ACA risk sharing provisions for the following asset (gross of any nonadmission) and liability balances along with the reasons for adjustments to prior year balance:

											alances as of
						ences	A	djustments			rting Date
	Year on Bus Before De	ring the Prior iness Written ecember 31	Current Year Written Before	Paid as of the r on Business e December 31	Prior Year Accrued Less Payments (Col 1 - 3)	Prior Year Accrued Less Payments (Col 2 - 4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)
		rior Year		rior Year	_	_	_	_			
	1	2	3	4	5	6	7	8		9	10
	Receivable	Payable	Receivable	Payable	Receivable	Payable	Receivable	Payable	Ref	Receivable	Payable
a. Permanent ACA Risk Adjustment Program											
Premium adjustments receivable (including high risk pool payments)	\$18,263,000	\$ -	\$20,809,584	\$ -	\$(2,546,584)	\$ -	\$ 2,546,584	\$ -	Α	\$ -	\$ -
Premium adjustments (payable) (including high risk pool premium)	\$ -	\$(1,470,000)	\$ -	\$(2,116,266)	\$ -	\$ 646,266	\$ -	\$ (646,266)	В	\$ -	\$ -
Subtotal ACA Permanent Risk Adjustment Program	\$18,263,000	\$(1,470,000)	\$20,809,584	\$(2,116,266)	\$(2,546,584)	\$ 646,266	\$ 2,546,584	\$ (646,266)		\$ -	\$ -
b. Transitional ACA Reinsurance Program					,						
Amounts recoverable for claims paid	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
Amounts recoverable for claims unpaid (contra liability)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
3. Amounts receivable relating to uninsured plans	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded											
premium	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
5. Ceded reinsurance premiums payable	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
6. Liability for amounts held under uninsured plans 7. Subtotal ACA	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
Transitional Reinsurance Program	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
c. Temporary ACA Risk Corridors Program											
1. Accrued retrospective premium 2. Reserve for rate credits	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
or policy experience rating refunds	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
3. Subtotal ACA Risk Corridors Program	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -		\$ -	\$ -
d. Total for ACA Risk Sharing Provisions	\$18,263,000	\$(1,470,000)	\$20,809,584	\$(2,116,266)	\$(2,546,584)	\$ 646,266	\$ 2,546,584	\$ (646,266)		\$ -	\$ -

Explanations of Adjustments:

- Revised data received
- B. Revised data received
- (4) Roll-Forward of Risk Corridors Asset and Liability Balances by Program Benefit Year

Not applicable

(5) ACA Risk Corridors Receivable as of Reporting Date

Not applicable

NOTE 25 Change in Incurred Claims and Claim Adjustment Expenses

A. Change in Incurred Claims and Claim Adjustment Expenses

The Company's reserves for incurred claims and claim adjustment expenses attributable to insured events of prior years have decreased by \$28,977,291 from \$247,796,540 in 2022. Because unpaid losses are estimated based on past experience and accumulated statistical data, the Company's actual benefit payments have varied from the original estimates.

B. Information About Significant Changes in Methodologies and Assumptions

There have been no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses.

NOTE 26 Intercompany Pooling Arrangements

Not applicable

NOTE 27 Structured Settlements

NOTE 28 Health Care Receivables

A. Pharmaceutical Rebate Receivables

Date	Estimated Pharmacy Rebates as Reported on Financial Statements	 Pharmacy bates as Billed or Otherwise Confirmed	Re	ctual Rebates eceived Within Days of Billing	Re	ctual Rebates eceived Within to 180 Days of Billing	R	ctual Rebates eceived More nan 180 Days After Billing
12/31/2023	\$ 80,197,209	\$ -	\$	3,521,287	\$	-	\$	-
09/30/2023	\$ 80,836,045	\$ 85,682,189	\$	72,868,862	\$	-	\$	-
06/30/2023	\$ 82,821,705	\$ 83,973,516	\$	73,459,588	\$	12,343,882	\$	-
03/31/2023	\$ 77,735,929	\$ 80,312,359	\$	68,991,085	\$	9,208,957	\$	68,971
12/31/2022	\$ 67,721,445	\$ 68,805,342	\$	-	\$	67,197,050	\$	1,498,761
09/30/2022	\$ 62,199,516	\$ 67,266,734	\$	-	\$	64,864,514	\$	2,413,224
06/30/2022	\$ 57,451,833	\$ 65,678,142	\$	-	\$	62,981,179	\$	2,804,470
03/31/2022	\$ 56,161,168	\$ 64,580,589	\$	-	\$	62,351,687	\$	2,153,166
12/31/2021	\$ 57,984,871	\$ 63,529,743	\$	-	\$	55,758,667	\$	7,872,869
09/30/2021	\$ 57,477,038	\$ 62,630,607	\$	-	\$	52,303,427	\$	10,080,915
06/30/2021	\$ 59,066,090	\$ 59,694,618	\$	-	\$	51,578,845	\$	8,395,478
03/31/2021	\$ 58,577,767	\$ 57,941,253	\$	-	\$	49,247,460	\$	8,815,277

B. Risk-Sharing Receivables

Not applicable

NOTE 29 Participating Policies

Not applicable

NOTE 30 Premium Deficiency Reserves

1. Liability carried for premium deficiency reserves

5

2. Date of the most recent evaluation of this liability

12/31/2023

3. Was anticipated investment income utilized in the calculation?

Yes [X] No []

NOTE 31 Anticipated Salvage and Subrogation

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer?						
1.2	If yes, did the reporting entity register and file with its domiciliary State Insura such regulatory official of the state of domicile of the principal insurer in the Providing disclosure substantially similar to the standards adopted by the Na its Model Insurance Holding Company System Regulatory Act and model regulatory and adopted subject to standards and disclosure requirements substantially similar to the	Holding Company System, a regis tional Association of Insurance Co gulations pertaining thereto, or is t	tration statement ommissioners (NAIC) in the reporting entity	Yes [X	[] No [] N/A []
1.3	State Regulating?				low	a	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?	?			Yes [] No [X]	
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued	d by the SEC for the entity/group.	<u> </u>				
2.1	Has any change been made during the year of this statement in the charter, reporting entity?				Yes [] No [X]	
2.2	If yes, date of change:		·····- –				
3.1	State as of what date the latest financial examination of the reporting entity v	vas made or is being made	······_		12/31/	2021	
3.2	State the as of date that the latest financial examination report became avail entity. This date should be the date of the examined balance sheet and not t				12/31/	2021	
3.3	State as of what date the latest financial examination report became available domicile or the reporting entity. This is the release date or completion date of examination (balance sheet date).	f the examination report and not the	ne date of the		03/20/	2023	
3.4	By what department or departments? Iowa Insurance Division and South Dakota Division of Insurance						
3.5	Have all financial statement adjustments within the latest financial examinati statement filed with Departments?			Yes [] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination repo	rt been complied with?		Yes [] No [] N/A [X]
4.1	During the period covered by this statement, did any agent, broker, sales reprombination thereof under common control (other than salaried employees a substantial part (more than 20 percent of any major line of business measured.) 4.11 sales of n	of the reporting entity), receive cre	dit or commissions for or c		Yes [] No [X]	
4.2	During the period covered by this statement, did any sales/service organizative receive credit or commissions for or control a substantial part (more than 20)		e reporting entity or an affi] No [X]	
		ew business?] No [X]] No [X]	
5.1	Has the reporting entity been a party to a merger or consolidation during the If yes, complete and file the merger history data file with the NAIC.	period covered by this statement	·		Yes [] No [X]	
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of dor ceased to exist as a result of the merger or consolidation.	nicile (use two letter state abbrevi	ation) for any entity that ha	s			
	1 Name of Entity	2 NAIC Company Code	3 State of Domicile				
6.1	Has the reporting entity had any Certificates of Authority, licenses or registra revoked by any governmental entity during the reporting period?				Yes [] No [X]	
6.2	If yes, give full information:						
7.1	Does any foreign (non-United States) person or entity directly or indirectly co				Yes [] No [X]	
7.2	If yes,				-		
	7.21 State the percentage of foreign control;	ty is a mutual or reciprocal, the na	tionality of its manager or		(0.0	_ %
	1 Nationality	2 Type of Er	titv				
		: ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					

8.1 8.2	Is the company a subsidiary of a depository institution holding compan If the response to 8.1 is yes, please identify the name of the DIHC.					Yes []	No [)	(]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fill fresponse to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	n (city and state of the main office) of any affiliates ru Office of the Comptroller of the Currency (OCC), the	egulated b	y a fed	leral	Yes []	No [)	(]
	1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC	;		
8.5	Is the reporting entity a depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding company with sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary sign Federal Reserve System or a subsidiary	olding company?				Yes []	No [)	(]
8.6	If response to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule?				es [] No [Х]	N/A	[]
9.	Ernst & Young LLP, 801 Grand Avenue, Des Moines, IA 50309	S							
10.1	Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Reporti law or regulation?	idit services provided by the certified independent p ing Model Regulation (Model Audit Rule), or substa	ublic acco	ountant ilar sta	te	Yes []	No [)	(]
10.2	If the response to 10.1 is yes, provide information related to this exemp	ption:							
	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin	milar state law or regulation?	Regulation	n as		Yes []	No [)	(]
10.4	If the response to 10.3 is yes, provide information related to this exemp	ption: 							
10.5 10.6	Has the reporting entity established an Audit Committee in compliance If the response to 10.5 is no or n/a, please explain.	e with the domiciliary state insurance laws?		Ү] No []	N/A	[]
11.	What is the name, address and affiliation (officer/employee of the repo- firm) of the individual providing the statement of actuarial opinion/certif Daniel J. Callahan, Senior Actuary, FSA, MAAA (employee), 1331 Gra	orting entity or actuary/consultant associated with ar fication?	n actuarial	consul	•				
12.1	Does the reporting entity own any securities of a real estate holding co	•				Yes [1	No [)	(1
	, , ,	estate holding company				.00 [,	,	
	12.12 Number of par	rcels involved				0			
	12.13 Total book/adj	justed carrying value				\$			0
12.2	If yes, provide explanation								
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI								
13.1	What changes have been made during the year in the United States m								
13.2	Does this statement contain all business transacted for the reporting en	entity through its United States Branch on risks when	rever locat	ted?		Yes []	No []
13.3						Yes []	No []
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the] No [.]	N/A	[]
14.1	Are the senior officers (principal executive officer, principal financial off similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual or relationships:	ich includes the following standards?				Yes [Х]	No []
	b. Full, fair, accurate, timely and understandable disclosure in the period. Compliance with applicable governmental laws, rules and regulation	ns;	ity;						
14.11	 d. The prompt internal reporting of violations to an appropriate person e. Accountability for adherence to the code. If the response to 14.1 is No, please explain: 	or persons identified in the code; and							
	Has the code of ethics for senior managers been amended?	nt(s).				Yes []	No [)	(]
	Have any provisions of the code of ethics been waived for any of the split the response to 14.3 is yes, provide the nature of any waiver(s).	pecified officers?				Yes []	No [)	(]

	1.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List?			Yes [] No	[X]	
J.Z		er of Credit and describe the circumstances in which the Lette					
	1 American Bankers Association (ABA) Routing	2		3	4	4	
	Number	Issuing or Confirming Bank Name		That Can Trigger the Letter of Credit		ount	
				,			
		BOARD O	F DIRECTOR	S			
6.		or sale of all investments of the reporting entity passed upon	•		Yes [X] No	[
7.	Does the reporti	ng entity keep a complete permanent record of the proceedin	gs of its board of dire	ectors and all subordinate committees	Yes [X] No	[
8.	part of any of its	g entity an established procedure for disclosure to its board o officers, directors, trustees or responsible employees that is i	in conflict or is likely	to conflict with the official duties of such	Yes [X	1 No	ſ
	person:				100 [7	, 110	
			ANCIAL				
9.	Has this stateme	ent been prepared using a basis of accounting other than Stat ciples)?	tutory Accounting Pri	nciples (e.g., Generally Accepted	Yes [1 No	[X
).1		aned during the year (inclusive of Separate Accounts, exclusiv					
				20.12 To stockholders not officers	\$		
				20.13 Trustees, supreme or grand (Fraternal Only)	\$		
).2	Total amount of	loans outstanding at the end of year (inclusive of Separate A	ccounts, exclusive of	:			
	policy loans):			20.21 To directors or other officers			
				20.22 To stockholders not officers			
1.1	Were any assets obligation being	s reported in this statement subject to a contractual obligation reported in the statement?	to transfer to anothe	er party without the liability for such			
1.2		amount thereof at December 31 of the current year:		21.21 Rented from others	\$		
				21.22 Borrowed from others			
				21.23 Leased from others			
	5		10	21.24 Other	\$		
2.1	Does this staten	nent include payments for assessments as described in the A ation assessments?	nnual Statement Inst	tructions other than guaranty fund or	Yes [X	1 No	ſ
2.2	If answer is yes:		22	2.21 Amount paid as losses or risk adjustment	\$	3	,567,
				2.22 Amount paid as expenses			
				2.23 Other amounts paid			
3.1		ng entity report any amounts due from parent, subsidiaries or	_		-	-	-
3.2 1.1	Does the insure	ny amounts receivable from parent included in the Page 2 am r utilize third parties to pay agent commissions in which the ar	mounts advanced by	the third parties are not settled in full within	\$ Yes [
1.2		o 24.1 is yes, identify the third-party that pays the agents and			162 [] 110	[\
			lo the				
		News of Third Date.	Is the Third-Party Age a Related Part				
		Name of Third-Party	(Yes/No)				
		INVE	STMENT				
.01		cks, bonds and other securities owned December 31 of currelession of the reporting entity on said date? (other than securiti			Yes [X	1 No	ſ

25.02	If no, give full and complete information, relating thereto					
25.03	For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)					
25.04	For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Cap Instructions.		\$			0
25.05	For the reporting entity's securities lending program, report amount of collateral for other programs.		\$			0
25.06	Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract?	es [] No	1	N/A [Х]
25.07	Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%?	es [] No []	N/A [Χ]
25.08	Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities lending Agreement (MSLA) to conduct securities lending?	es [] No]	N/A [Х]
25.09	For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:					
	 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2. Total book/adjusted carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2. Total payable for securities lending reported on the liability page. 	\$				0
26.1	Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 25.03).		Yes [X] N	lo []
26.2	If yes, state the amount thereof at December 31 of the current year: 26.21 Subject to reverse repurchase agreements	dged to	\$ \$ \$ \$ \$ \$ \$		2,148	0 0 0 ,700 0
26.3	For category (26.26) provide the following:					
	To datagory (20.20) provide the following.					
	1 2 Nature of Restriction Description			3 nount		
	1 2 Nature of Restriction Description			nount]
27.1 27.2	1 2 Description Does the reporting entity have any hedging transactions reported on Schedule DB?		Yes [nount 	lo [X	
27.1 27.2	1 2 Description Does the reporting entity have any hedging transactions reported on Schedule DB?		Yes [nount 	lo [X	
27.1 27.2	1 2 Nature of Restriction Description Does the reporting entity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Ye If no, attach a description with this statement.	 es [Yes [] N	lo [X N/A [Х]
27.1 27.2 JINES 2	Nature of Restriction Does the reporting entity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Ye If no, attach a description with this statement.	es [Yes [] N	lo [X N/A [lo [Х]
27.1 27.2 LINES 2 27.3	Nature of Restriction Does the reporting entity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary state?	es [////////////////////////////////////	Yes [Yes [Yes [Yes [Yes [] N] N] N] N	lo [X N/A [lo [o [o [o [Х]
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction Does the reporting entity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Ye If no, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108	es [////////////////////////////////////	Yes [Yes [Yes [Yes [] N] N] N] N	lo [X N/A [0 0 [0 0 [0 0 [X]
27.1 27.2 INES 2 27.3 27.4	Does the reporting entity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Ye If no, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108. 27.42 Permitted accounting practice 27.43 Other accounting guidance. By responding YES to 27.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following: • The reporting entity has obtained explicit approval from the domiciliary state. • Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21. • Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-2 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount. • Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the	es [Yes [Yes [Yes [Yes [Yes [Yes [] N] N] N	N/A	X]]]]]
27.1 27.2 LINES 2 27.3 27.4 27.5	Nature of Restriction Does the reporting entity have any hedging transactions reported on Schedule DB? If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? Ye If no, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY: Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity. If the response to 27.3 is YES, does the reporting entity utilize: 27.41 Special accounting provision of SSAP No. 108	es [iy? 21 d in ne iity's	Yes [Yes [Yes [Yes [Yes [Yes [] N] N] N] N	N/A	X]]]]]0

GENERAL INTERROGATORIES

29.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1 ,	2	3
Name(s)	Location(s)	Complete Explanation(s)

29.03 Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?..... Yes [] No [X]

29.04 If yes, give full and complete information relating thereto:

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
NISA Investment Advisors, LLC	U
Wellington Management Company LLP	U
William Blair Investment Management, LLC	
BlackRock Financial Management, Inc.	U
Metropolitan West Asset Management, LLC	U
Pyrford International, Ltd.	U
Broadridge Business Process Outsourcing, LLC	U
Cardinal Investment Advisors, LLC	
Mercer Investments LLC	U
Wellmark, Inc.	I

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") manage more than 10% of the reporting entity's invested assets?.. Yes [X] No []

29.0598 For firms/individuals unaffiliated with the reporting entity (i.e. designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?..... Yes [X] No []

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
107313	NISA Investment Advisors, LLC	549300L1IG2J0W7XNY28	SEC	NO
106595	Wellington Management Company LLP	549300YHP12TEZNLCX41	SEC	NO
173961	William Blair Investment Management, LLC	549300VQX7UK060A7X27	SEC	NO
107105	BlackRock Financial Management, Inc	549300LVXY1VJKE13M84	SEC	NO
104571	Metropolitan West Asset Management, LLC	5493004MDKGXC001Y283	SEC	NO
105646	Pyrford International, Ltd	549300N5W87B21SAUG48	SEC	NO
114212	Broadridge Business Process Outsourcing, LLC	213800WWTABZ1G0JHH37	SEC	NO
116418	Cardinal Investment Advisors, LLC		SEC	NO
133449	Mercer Investments LLC	549300EH2E3BU0C07W92	SEC	NO

30.1

Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? Yes [X] No []

30.2 If yes, complete the following schedule:

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
72201F-49-0	PIMCO Income Inst!	158,625,129
969251-50-3	William Blair Emerging Markets	50,903,046
30.2999 - Total		209.528.175

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	5
Name of Mutual Fund (from above table)	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation
RINOS Income Instit	Uniform Mortgage-Backed Security TBA 5.500% due	44 054 004	00 (00 (0000
PIMCO Income Inst!	09/01/2053 - 11/01/2053 TRA 0.000% -	11,051,064	09/30/2023
BUILDO I	Uniform Mortgage-Backed Security TBA 6.000% due	10 110 050	00 (00 (0000
PIMCO Income Inst!	10/01/2053 - 11/01/2053		09/30/2023
PIMCO Income Inst!	PIMCO Short-Term Floating NAV Portfolio III	9,495,705	09/30/2023
	Uniform Mortgage-Backed Security TBA 4.000% due		
PIMCO Income Inst!	10/01/2053 - 11/01/2053	5,703,427	09/30/2023
	Uniform Mortgage-Backed Security TBA 5.000% due		
PIMCO Income Instl	10/01/2053 - 11/01/2053		09/30/2023
William Blair Emerging Markets	Taiwan Semiconductor Manufacturing Co. Ltd		09/30/2023
William Blair Emerging Markets	Tencent Holdings Ltd.		09/30/2023
William Blair Emerging Markets	Samsung Electronics Co.	2,392,443	09/30/2023
William Blair Emerging Markets	PT Bank Central Asia Tbk	2 . 188 . 831	09/30/2023
William Blair Emerging Markets	HDFC Bank Ltd.	2,188,831	09/30/2023

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	1,055,782,269	1,024,263,499	(31,518,770)
31.2 Preferred stocks	1,721,443	1,721,443	0
31.3 Totals	1,057,503,712	1,025,984,942	(31,518,770)

31.4	Describe the sources or methods utilized in determining the fair values: The Company obtains at least one price from a third party pricing service or its custodian, which also uses a pricing service. In most instances, the Company obtains more than one price and evaluates between the pricing sources for any outliers or stale prices. Assuming prices are not stale and are reasonable between sources, the Company follows a pre-established hierarchy to determine which pricing source to utilize.			
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes [)	(]	No []
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes [)	(]	No []
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:			
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Yes [)	(]	No []
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.			
	Has the reporting entity self-designated 5GI securities?	Yes []	No [X]
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities?	Yes []	No [X]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.			
	 d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? 	Yes []	No [X]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?	1 No I	1	N/A I Y
	140 L	, [,	, _L

38.1	Does the reporting entity directly hold cryptocurrencies?			Yes [] No [X]
38.2	If the response to 38.1 is yes, on what schedule are they reported?				
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for pro-	remiums on policies?		Yes [] No [X]
39.2		tely converted to U.S. dollars?		Yes [Yes [] No []] No []
39.3	If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of	premiums or that are held directly	<i>i</i> .		
	1 Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepted for Payment of Premiums		
	OTHER				
40.1 40.2	Amount of payments to trade associations, service organizations and statistical or rating List the name of the organization and the amount paid if any such payment represented service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations and statistical or rating bureaus during the period covered by this service organizations are service organizations.	25% or more of the total paymer statement.	ats to trade association 2 at Paid .1,220,926		1,529,238
41.1	Amount of payments for legal expenses, if any?			\$	2,500,844
41.2	List the name of the firm and the amount paid if any such payment represented 25% or during the period covered by this statement.	more of the total payments for leg	gal expenses		
	1 Name		2 nt Paid		
	Nyemaster Goode		646,569		
42.1	Amount of payments for expenditures in connection with matters before legislative bodie	es, officers or departments of gov	ernment, if any?	\$	117,207
42.2	List the name of the firm and the amount paid if any such payment represented 25% or connection with matters before legislative bodies, officers, or departments of governments.				
	1 Name	Amou	2 nt Paid 		

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1		he reporting entity have any direct Medicare Supplement Insurance in force?				
1.2 1.3		Indicate premium earned on U.S. business onlyortion of Item (1.2) is not reported on the Medicare Supplement Insurance Exp				665,535 0
1.3		teason for excluding	enerice Exhibit?	Ф		
1.4		e amount of earned premium attributable to Canadian and/or Other Alien not in				0
1.5	Indicate	e total incurred claims on all Medicare Supplement Insurance		. \$	389,	792,370
1.6	Individ	ual policies:	Most current three years:			
			1.61 Total premium earned			
			1.62 Total incurred claims	•	,	,
			1.63 Number of covered lives			. 24 , 199
			All years prior to most current three years:			
			1.64 Total premium earned			
			1.65 Total incurred claims			
			1.66 Number of covered lives			130,344
	_					
1.7	Group	policies:	Most current three years:			
			1.71 Total premium earned			
			1.72 Total incurred claims			
			1.73 Number of covered lives			0
			All years prior to most current three years:			_
			1.74 Total premium earned			
			1.75 Total incurred claims	-		
			1.76 Number of covered lives			0
_		T				
2.	Health	l est:	1 2			
			1 2 Current Year Prior Year			
	2.1 I	Premium Numerator				
		Premium Denominator				
		Premium Ratio (2.1/2.2)				
	2.4	Reserve Numerator				
	2.5 I	Reserve Denominator				
		Reserve Ratio (2.4/2.5)				
3.1	Has the	e reporting entity received any endowment or gift from contracting hospitals, ph	ysicians, dentists, or others that is agreed will be	l ooV	1 No	r v 1
	returne	d when, as and if the earnings of the reporting entity permits?		Yes [] INO	[X]
3.2	If woo	rivo particulare:				
3.2		give particulars:				
4.1	Have c	opies of all agreements stating the period and nature of hospitals', physicians',	and dentists' care offered to subscribers and			
7.1		dents been filed with the appropriate regulatory agency?		Yes [X] No	[]
4.2	If not p	reviously filed, furnish herewith a copy(ies) of such agreement(s). Do these agr	reements include additional benefits offered?	Yes [X] No	[]
5.1	Does the	ne reporting entity have stop-loss reinsurance?		Yes [] No	[X]
5.2	If no, e					
	The Co	ompany retains all risk.				
5.3	Maxim	um retained risk (see instructions)	5.31 Comprehensive Medical			
			5.32 Medical Only	. \$		0
			5.33 Medicare Supplement	.\$	9,	999,999
			5.34 Dental & Vision	. \$	9,	999,999
			5.35 Other Limited Benefit Plan			
			5.36 Other	.\$		0
6.		be arrangement which the reporting entity may have to protect subscribers and				
	noid na agreen	armless provisions, conversion privileges with other carriers, agreements with p	providers to continue rendering services, and any other			
	•	res exceed all regulatory requirements. Member of lowa Life & Health Insurance	e Guaranty Association under lowa Code 508C			
	reserv	es exceed an regulatory requirements. Member of lower life a ricalar modification	oc duranty / 3300iation ander lower code cooc			
7.1	Does t	ne reporting entity set up its claim liability for provider services on a service date	e basis?	Yes [X	1 No	[]
7.2	If no, g	ive details				
8.	Provide	e the following information regarding participating providers:	8.1 Number of providers at start of reporting year			
			8.2 Number of providers at end of reporting year .			9,606
9.1	Does t	ne reporting entity have business subject to premium rate guarantees?		Yes [] No	[X]
9.2	If yes,		9.21 Business with rate guarantees between 15-36 months			
		9	9.22 Business with rate guarantees over 36 months	\$		0

10.1	Does the reporting entity have Incentive Pool, Withhou	old or Bonus Arr	rangements in its	orovider contracts?	·		Yes [X]	No []
10.2	If yes:		1 1	0.22 Amount actua 0.23 Maximum am	ount payable bonu ally paid for year bo ount payable withh ally paid for year wit	nusesolds	\$	0
11.1	Is the reporting entity organized as:			11.13 An Indivi	al Group/Staff Mode dual Practice Asso Model (combination	ciation (IPA), or,	Yes [] Yes [] Yes []	No [X] No [X] No [X]
11.2 11.3 11.4	Is the reporting entity subject to Statutory Minimum C If yes, show the name of the state requiring such mir If yes, show the amount required.	nimum capital ar	nd surplus				\$	10WA 5,000,000
11.5 11.6	Is this amount included as part of a contingency reself the amount is calculated, show the calculation	erve in stockhold	er's equity?				Yes []	No [X]
12.	List service areas in which reporting entity is licensed	d to operate:						
			1 Name of Service	e Area				
	South Dak	ota						
13.1	Do you act as a custodian for health savings account	ts?					Yes []	No [X]
13.2	If yes, please provide the amount of custodial funds l	held as of the re	porting date				\$	0
13.3	Do you act as an administrator for health savings acc	counts?					Yes []	No [X]
13.4	If yes, please provide the balance of funds administe	ered as of the rep	oorting date				\$	0
14.1 14.2	Are any of the captive affiliates reported on Schedule If the answer to 14.1 is yes, please provide the follow		orized reinsurers?			Yes [] No [] N/A [X]
	1	2	3	4		Supporting Reserv		
		NAIC Company	Domiciliary	Reserve	5 Letters of	6 Trust	7	
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other	
15.	Provide the following for individual ordinary life insura ceded):	ance* policies (l	J.S. business only) for the current ye	ar (prior to reinsura	nce assumed or		
					Direct Premium Wri			
					Total Incurred Clain			
				15.3 N	Number of Covered	Lives		0
		*Ordin	nary Life Insurance	Includes				
	Term(whether full und	lerwriting, limited	d underwriting, jet	issue, "short form a				
	Whole Life (whether fu			ng, jet issue, "short	form app")			
	Universal Life (with or Variable Universal Life	without seconda	ary gurarantee)	antee)				
16.	Is the reporting entity licensed or chartered, registered	ed, qualified, elig	ible or writing bus	iness in at least tw	o states?		Yes [X] No	[]
16.1	If no, does the reporting entity assume reinsurance be domicile of the reporting entity?					ate of	Yes [] No	[]

FIVE-YEAR HISTORICAL DATA

		1 2023	2 2022	3 2021	4 2020	5 2019
	Balance Sheet (Pages 2 and 3)	2020	2022	2021	2020	2010
1.	Total admitted assets (Page 2, Line 28)	3 907 004 071	3 308 799 411	3 289 273 666	2 954 103 558	2 762 240 921
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement					
4.	Total capital and surplus (Page 3, Line 33)					
4.	Income Statement (Page 4)	2,040,004,000	2,200,701,700	2,017,770,333	2,023,004,040	1,000,000,000
5	Total revenues (Line 8)	2 621 830 006	2 570 574 724	2 551 895 501	2 534 234 453	2 560 232 134
5. 6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
	Total other income (Lines 28 plus 29)					
11.	Net income or (loss) (Line 32)					
12.		2 10,333, 140	62,306,021	143,344,014	130,322,230	130,092,202
40	Cash Flow (Page 6) Net cash from operations (Line 11)	70 600 010	(72 507 001)	76 504 564	21 042 504	75 420 066
13.			(13,361,961)		21,942,304	73,420,900
1.1	Risk-Based Capital Analysis Total adjusted capital	2 650 266 255	2 200 701 706	2 217 772 500	2 025 264 642	1 052 666 062
14.	Authorized control level risk-based capital					
15.		232,012,649	213,600,296	210,001,307	100,444,023	103,061,760
16	Enrollment (Exhibit 1) Total members at end of period (Column 5, Line 7).	1 129 626	1 122 224	1 150 270	1 100 050	1 212 004
16.	Total members at end of period (Column 5, Line 7). Total members months (Column 6, Line 7)					
17.	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0	10,300,303	10,001,132	10,004,071	14,024,110	14,003,144
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	85.8	87.1	86.7	85.3	84.8
20.	Cost containment expenses	0.8	0.7	0.8	0.8	0.8
21.	Other claims adjustment expenses	2.5	2.4	2.7	3.1	3.1
22.	Total underwriting deductions (Line 23)	96.7	98.0	98.2	100.0	97.6
23.	Total underwriting gain (loss) (Line 24)	3.3	2.0	1.8	0.1	2.4
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	185,513,762	332,241,815	295 , 110 , 958	339,023,075	320,806,165
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	132,229,382	283,296,128	254,009,736	283,079,231	304,814,070
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)					
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31					
33.	Total investment in parent included in Lines 26 to	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	. , ,	,:,	1 1,522, 111	, , ,
	31 above. If a party to a merger, have the two most recent years	0	0	0	0	0

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS

Allocated by States and Territories

	Allocated by States and Territories 1 Direct Business Only											
	1							9	10			
1.	States, etc.	AL	Active Status (a)	Accident and Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Benefits Program Premiums	Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 8	Deposit-Type Contracts
2.	Alaska	AK	N	0	0	0	0	0	0	0	0	0
3.	Arizona	AZ	N	0	0	0	0	0	0	0	0	0
4.	Arkansas	AR	N	0	0	0	0	0	0	0	0	0
5.	California	CA	N	0	0	0	0	0	0	0	0	0
6.	Colorado	CO	N	0	0	0	0	0	0	0	0	0
7. 8.	Connecticut Delaware	CT DE	N N		0	0 0	0	0	0	0	0	0
9.	District of Columbia	DC	N			0	٥		0	0 n	n	0
	Florida	FL	N	0	0	0	0	0	0	0	0	0
11.	Georgia	GA	N	0	0	0	0	0	0	0	0	0
12.	Hawaii	HI	N	0	0	0	0	0	0	0	0	0
13.	Idaho	ID	N	0	0	0	0	0	0	0	0	0
	Illinois	IL	N	0	0	0	0	0	0	0	0	0
	Indiana	IN	N	0	0	0	0	0	0	0	0	0
16.	lowa	IA	N	2,232,641,231	0	0 0	0	319,649,085	0	0	2,552,290,316	0
17. 18.	Kansas Kentucky	KS KY	N N		0	0	 n	n	0	0 n	J	 n
	Louisiana	LA	N	0	0	0	0	0	0	0	0	0
	Maine	ME	N	0	0	0	0	0	0	0	0	0
21.	Maryland	MD	N	0	0	0	0	0	0	0	0	0
22.	Massachusetts	MA	N	0	0	0	0	0	0	0	0	0
	Michigan	MI	N	0	0	0	0	0	0	0	0	0
	Minnesota	MN	N	0	0	0	0	0	0	0	0	0
	Mississippi	MS	N N	0	0	0	0	0	0	0	0	0
26. 27.	Missouri Montana	MO MT	N			0 0			0			
28.	Nebraska	NE	N N			0				n	n	٥
	Nevada	NV	N	0	0	0	0	0	0	0	0	0
	New Hampshire		N	0	0	0	0	0	0	0	0	0
31.	New Jersey		N	0	0	0	0	0	0	0	0	0
32.	New Mexico	NM	N	0	0	0	0	0	0	0	0	0
33.	New York	NY	N	0	0	0	0	0	0	0	0	0
34.	North Carolina	NC	N	0	0	0	0	0	0	0	0	0
35. 36.	North Dakota	ND	N N	0	0	0 0	0	0	0	0	0	0
37.	Ohio Oklahoma	OH OK	N N			0	٥		0			٥
38.	Oregon	OR	N N			0			0	n	n	0
	Pennsylvania	PA	N	0	0	0	0	0	0	0	0	0
	Rhode Island		N	0	0	0	0	0	0	0	0	0
41.	South Carolina	SC	N	0	0	0	0	0	0	0	0	0
42.	South Dakota	SD	L	62,889,096	0	0	0	0	0	0	62,889,096	0
	Tennessee	TN	N	0	0	0	0	0	0	0	0	0
44.	Texas	TX	N	0	0	0	0	0	0	0	0	0
	Utah	UT	N	0	0 0	0	0 0	0 0	0	0	0	0
	Vermont Virginia	VT VA	N	0	0	0 0	0	0	0	0	0	0
	Washington	WA	N	0	0	0	0	0	0	0	0	0
	West Virginia		N	0	0	0	0	0	0	0	0	0
	Wisconsin		N	0	0	0	0	0	0	0	0	0
51.	Wyoming	WY	N	0	0	0	0	0	0	0	0	0
52.	American Samoa		N	0	0	0	0	0	0	0	0	0
	Guam	GU	N	0	0	0	0	0	0	0	0	0
	Puerto Rico		N	0	0	0	0	0	0	0	0	0
	U.S. Virgin Islands Northern Mariana	VI	N	0	0	0	0	0	0	0	0	0
50.	Islands	MP	N	0	0	0	0	0	0	0	0	0
57.	Canada		N	0	0	0	0	0	0	0	0	0
58.	Aggregate Other				_		e e					-
E0	Aliens		XXX	2 205 520 227	0 0	0 0	0 0	0	0	0	2 615 170 412	0
59. 60.	Subtotal Reporting Entity Contributions for Er	nployee		2,295,530,327							2,615,179,412	0
•	Benefit Plans		XXX	0	0	0	0	0	0	0	0	0
61.	Totals (Direct Busine		XXX	2,295,530,327	0	0	0	319,649,085	0	0	2,615,179,412	0
58001.	DETAILS OF WRITE		XXX									
58001.			XXX									
58003.			XXX									
	Summary of remaining write-ins for Line 58 f	ng		0	0	0	0	0	0	0		
58999.	Totals (Lines 58001 58003 plus 58998)(L		XXX								0	0
	above) e Status Counts:		XXX	0	0	0	0	0	0	0	0	0


^{3.} E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. 0

⁽b) Explanation of basis of allocation by states, premiums by state, etc.

Accident and Health premiums are allocated according to the location of the group or individual purchaser at the point of issue.

SCHEDULE Y - INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP

PART 1 – ORGANIZATIONAL CHART



OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Assets Line 25

/ taaitioi	Additional Write in 3 for 763cts Elife 20								
			Current Year						
		1	2	3	4				
				Net Admitted Assets	Net Admitted				
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets				
2504.	Miscellaneous Assets	1,938,165	1,425,895	512,270	507,584				
2597.	Summary of remaining write-ins for Line 25 from overflow page	1,938,165	1,425,895	512,270	507,584				

Additional Write-ins for Liabilities Line 23

			Prior Year		
		1	2	3	4
		Covered	Uncovered	Total	Total
2304.	Escheat Liability	3,018,294	0	3,018,294	2,471,156
2397.	Summary of remaining write-ins for Line 23 from overflow page	3,018,294	0	3,018,294	2,471,156

A dditional	Mrita ina fa	- Cubibit of	Nanadmittad	Assets Line 25
Additional	vvrite-ins to	r ⊢xninit ot	Nonadmitted	Assets Line 25

	idi vviite ille for Exhibit of Norladifitted / 1000to Elife 20			
		1	2	3
				Change in Total
		Current Year Total	Prior Year Total	Nonadmitted Assets
		Nonadmitted Assets	Nonadmitted Assets	(Col. 2 - Col. 1)
2504.	Miscellaneous Assets	1,425,895	1,523,208	97,313
2597.	Summary of remaining write-ins for Line 25 from overflow page	1,425,895	1,523,208	97,313